US8445475B2 - Supramolecular complexes as photoactivated DNA cleavage agents - Google Patents
Supramolecular complexes as photoactivated DNA cleavage agents Download PDFInfo
- Publication number
- US8445475B2 US8445475B2 US12/610,729 US61072909A US8445475B2 US 8445475 B2 US8445475 B2 US 8445475B2 US 61072909 A US61072909 A US 61072909A US 8445475 B2 US8445475 B2 US 8445475B2
- Authority
- US
- United States
- Prior art keywords
- metal
- dpp
- dna
- bpm
- rhcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- 230000007018 DNA scission Effects 0.000 title description 8
- 229910052751 metal Inorganic materials 0.000 claims abstract description 118
- 239000002184 metal Substances 0.000 claims abstract description 103
- 239000003446 ligand Substances 0.000 claims abstract description 90
- 238000012546 transfer Methods 0.000 claims abstract description 41
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 128
- 238000000034 method Methods 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 30
- WTZDTUCKEBDJIM-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyrazine Chemical compound N1=CC=CC=C1C1=NC=CN=C1C1=CC=CC=N1 WTZDTUCKEBDJIM-UHFFFAOYSA-N 0.000 claims description 28
- DRGAZIDRYFYHIJ-UHFFFAOYSA-N 2,2':6',2''-terpyridine Chemical compound N1=CC=CC=C1C1=CC=CC(C=2N=CC=CC=2)=N1 DRGAZIDRYFYHIJ-UHFFFAOYSA-N 0.000 claims description 27
- 238000003776 cleavage reaction Methods 0.000 claims description 24
- 230000007017 scission Effects 0.000 claims description 23
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 12
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 9
- YAYGSLOSTXKUBW-UHFFFAOYSA-N ruthenium(2+) Chemical compound [Ru+2] YAYGSLOSTXKUBW-UHFFFAOYSA-N 0.000 claims description 9
- PZSJYEAHAINDJI-UHFFFAOYSA-N rhodium(3+) Chemical compound [Rh+3] PZSJYEAHAINDJI-UHFFFAOYSA-N 0.000 claims description 8
- ILLTYNYTHFEGHK-UHFFFAOYSA-N 2,3-bis(2-pyridinyl)quinoxaline Chemical compound N1=CC=CC=C1C1=NC2=CC=CC=C2N=C1C1=CC=CC=N1 ILLTYNYTHFEGHK-UHFFFAOYSA-N 0.000 claims description 6
- MILUBEOXRNEUHS-UHFFFAOYSA-N iridium(3+) Chemical compound [Ir+3] MILUBEOXRNEUHS-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical compound [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 claims description 5
- LVTCZSBUROAWTE-UHFFFAOYSA-N diethyl(phenyl)phosphane Chemical compound CCP(CC)C1=CC=CC=C1 LVTCZSBUROAWTE-UHFFFAOYSA-N 0.000 claims description 5
- 230000003211 malignant effect Effects 0.000 claims description 5
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims description 5
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical compound [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 claims description 5
- OJNBAGCXFHUOIQ-UHFFFAOYSA-N [Re+] Chemical compound [Re+] OJNBAGCXFHUOIQ-UHFFFAOYSA-N 0.000 claims description 4
- XQBKHDFIPARBOX-UHFFFAOYSA-N osmium(3+) Chemical compound [Os+3] XQBKHDFIPARBOX-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000000260 Warts Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000010153 skin papilloma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 48
- 229910052707 ruthenium Inorganic materials 0.000 abstract description 16
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract description 14
- 229910001882 dioxygen Inorganic materials 0.000 abstract description 12
- 230000000975 bioactive effect Effects 0.000 abstract description 3
- 229910052762 osmium Inorganic materials 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 76
- 239000010948 rhodium Substances 0.000 description 76
- 108020004414 DNA Proteins 0.000 description 64
- 239000000370 acceptor Substances 0.000 description 52
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 40
- 239000013612 plasmid Substances 0.000 description 29
- 230000007704 transition Effects 0.000 description 29
- 150000004696 coordination complex Chemical class 0.000 description 21
- 229910052703 rhodium Inorganic materials 0.000 description 21
- 230000009467 reduction Effects 0.000 description 18
- 230000010076 replication Effects 0.000 description 18
- 239000006096 absorbing agent Substances 0.000 description 17
- 230000005284 excitation Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 238000004768 lowest unoccupied molecular orbital Methods 0.000 description 15
- 230000005281 excited state Effects 0.000 description 14
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 13
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 12
- 230000001482 DNA photocleavage Effects 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000003504 photosensitizing agent Substances 0.000 description 10
- 229910021640 Iridium dichloride Inorganic materials 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000027756 respiratory electron transport chain Effects 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 229910001868 water Inorganic materials 0.000 description 9
- HKOAFLAGUQUJQG-UHFFFAOYSA-N 2-pyrimidin-2-ylpyrimidine Chemical compound N1=CC=CN=C1C1=NC=CC=N1 HKOAFLAGUQUJQG-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000004770 highest occupied molecular orbital Methods 0.000 description 8
- 230000002427 irreversible effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- -1 dpp (A) Chemical compound 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 238000002428 photodynamic therapy Methods 0.000 description 7
- 229910021607 Silver chloride Inorganic materials 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002484 cyclic voltammetry Methods 0.000 description 6
- 238000001663 electronic absorption spectrum Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- HSSMNYDDDSNUKH-UHFFFAOYSA-K trichlororhodium;hydrate Chemical compound O.Cl[Rh](Cl)Cl HSSMNYDDDSNUKH-UHFFFAOYSA-K 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 229910018965 MCl2 Inorganic materials 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000005518 electrochemistry Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- IUEQMQXAVZARKU-UHFFFAOYSA-N 2-pyridin-2-ylpyrazine Chemical compound N1=CC=CC=C1C1=CN=CC=N1 IUEQMQXAVZARKU-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000005868 electrolysis reaction Methods 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000006303 photolysis reaction Methods 0.000 description 3
- 230000015843 photosynthesis, light reaction Effects 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 125000004424 polypyridyl Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 229910021135 KPF6 Inorganic materials 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229910052741 iridium Inorganic materials 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- MQZFZDIZKWNWFX-UHFFFAOYSA-N osmium(2+) Chemical compound [Os+2] MQZFZDIZKWNWFX-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000010405 reoxidation reaction Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000003115 supporting electrolyte Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- LCPZKRMXSGJLTO-UHFFFAOYSA-N 2,3-dipyridin-2-ylbenzo[f]quinoxaline Chemical compound N1=CC=CC=C1C1=NC2=CC=C(C=CC=C3)C3=C2N=C1C1=CC=CC=N1 LCPZKRMXSGJLTO-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108091027569 Z-DNA Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- XKRSCNHZIJKIKQ-UHFFFAOYSA-N [N].C1=CN=CC=N1 Chemical compound [N].C1=CN=CC=N1 XKRSCNHZIJKIKQ-UHFFFAOYSA-N 0.000 description 1
- 239000005092 [Ru (Bpy)3]2+ Substances 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000010411 electrocatalyst Substances 0.000 description 1
- 238000000426 electronic spectroscopy Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229910021397 glassy carbon Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ASBFNPBREVZDOE-UHFFFAOYSA-N phenanthrene-9,10-diimine Chemical compound C1=CC=C2C(=N)C(=N)C3=CC=CC=C3C2=C1 ASBFNPBREVZDOE-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001443 photoexcitation Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002468 redox effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- SONJTKJMTWTJCT-UHFFFAOYSA-K rhodium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Rh+3] SONJTKJMTWTJCT-UHFFFAOYSA-K 0.000 description 1
- 150000003303 ruthenium Chemical class 0.000 description 1
- LMYKTNLGBUMKNF-UHFFFAOYSA-N ruthenium(1+) Chemical compound [Ru+] LMYKTNLGBUMKNF-UHFFFAOYSA-N 0.000 description 1
- BIXNGBXQRRXPLM-UHFFFAOYSA-K ruthenium(3+);trichloride;hydrate Chemical compound O.Cl[Ru](Cl)Cl BIXNGBXQRRXPLM-UHFFFAOYSA-K 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/002—Osmium compounds
- C07F15/0026—Osmium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0073—Rhodium compounds
- C07F15/008—Rhodium compounds without a metal-carbon linkage
Definitions
- the invention generally relates to photodynamic therapy agents.
- the invention provides tunable supramolecular metallic complexes which can be activated to cleave DNA by low energy light and in the absence of O 2 .
- Photodynamic therapy is currently gaining acceptance for the treatment of hyperproliferating tissues such as cancers and non-malignant lesions.
- Photochemical approaches are of particular interest as they offer reaction control and can be highly targeted.
- photodynamic agents One popular approach in the design of photodynamic agents involves the sensitization of molecular oxygen. Typically, such agents absorb light energy and transfer that energy to molecular oxygen to generate a reactive singlet oxygen state 1 O 2 .
- the 1 O 2 state is highly reactive and, in an intracellular environment, 1 O 2 randomly reacts with and damages biomolecules and subcellular components, leading to potentially lethal damage to the cell.
- the use of such agents has several drawbacks.
- the wavelengths of light that must be used to activate this type of photodynamic agent are short wavelength/high energy and cause extensive damage to healthy tissue adjacent to the targeted, hyperproliferating cells.
- the targeted cell may lyse, releasing 1 O 2 into the immediate environment where it continues to react randomly with and damage healthy tissue in the area.
- such agents require the presence of oxygen, the level of which is relatively low in an intracellular environment.
- photosensitizing agents for photodynamic therapy with alternative mechanisms of action.
- the use of photosensitizing agents that absorb low energy light is less likely to cause unwanted collateral damage to non-targeted cells in a photodynamic therapy setting.
- the present invention provides novel metal-based DNA cleaving agents.
- the agents are supramolecular metallic complexes containing at least one metal to ligand charge transfer (MLCT) light absorbing metal, at least one bridging T-acceptor ligand, and an electron acceptor metal.
- MLCT metal to ligand charge transfer
- the complexes are capable of effecting the cleavage of DNA upon exposure to low energy visible light, and do so in the absence of oxygen.
- the invention provides new compositions of matter of the forms:
- composition comprising at least one of the above compounds dissolved or dispersed in a carrier.
- the invention further provides a method for cleaving DNA.
- the method includes the steps of combining the DNA with a supramolecular complex.
- the complex contains at least one metal to ligand charge transfer (MLCT) light absorbing metal, at least one bridging i-acceptor ligand, and an electron acceptor metal.
- the step of combining is carried out under conditions that allow the supramolecular complex to bind to the DNA, and the supramolecular complex is present in sufficient quantity to cleave said DNA.
- the second step of the method is exposing the DNA to light or radiant energy in an amount sufficient to activate the supramolecular complex to cleave the DNA.
- the metal to ligand charge transfer (MLCT) light absorbing metal may be, for example, ruthenium(II), osmium(III), rhenium(I), iron(II) or platinum(II).
- the bridging ⁇ -acceptor ligand may be, for example, 2,3-bis(2-pyridyl)pyrazine; 2,2′-bipyridimidine; 2,3-bis(2-pyridyl)quinoxaline; or 2,3,5,6,-tetrakis(2-pyridyl)pyrazine.
- the electron acceptor metal may be, for example, rhodium(III), platinum(IV), cobalt(III), or iridium(III).
- the supramolecular complex may further include at least one terminal ⁇ -acceptor ligand, in which case the terminal ⁇ -acceptor ligand may be, for example, 2,2′-bipyridine; 2,2′:6′,2′′-terpyridine; triphenylphosphine; and 2,2′-phenylpyridine or diethylphenylphosphine.
- the light used to activate the complex is visible light.
- the supramolecular complex utilized in the method may be, for example, [(2,2′-bipyridine) 2 Ru(2-pyridyl)pyrazine)RhCl 2 (2-pyridyl)pyrazine)Ru(2,2′-bipyridine) 2 ](PF 6 ) 5 ; [(2,2′-bipyridine) 2 Os(2,3-bis(2-pyridyl)pyrazine)RhCl 2 (2,3-bis(2-pyridyl)pyrazine)Os(2,2′-bipyridine) 2 ](PF 6 ) 5 ; [(2,2′:6′,2′′-terpyridine)RuCl(2,3-bis(2-pyridyl)pyrazine)RhCl 2 (2,3-bis (2-pyridyl)pyrazine)RuCl(2,2′:6′,2′′-terpyridine)](PF 6 ) 3 ; or [(2,2′:
- the invention also provides a composition for effecting the cleavage of DNA in hyperproliferating cells.
- the composition contains a supramolecular complex comprising at least one metal to ligand charge transfer (MLCT) light absorbing metal; at least one bridging n-acceptor ligand; and an electron acceptor metal.
- the metal to ligand charge transfer (MLCT) light absorbing metal may be ruthenium(II), osmium(III), rhenium(I), iron(II) or platinum(II).
- the bridging ⁇ -acceptor ligand may be 2,3-bis(2-pyridyl)pyrazine; 2,2′-bipyridimidine; 2,3-bis(2-pyridyl) quinoxaline; or 2,3,5,6,-tetrakis(2-pyridyl)pyrazine.
- the electron acceptor metal may be rhodium(III), platinum(IV), cobalt(III), or iridium(III).
- the supramolecular complex may further comprises at least one terminal ⁇ -acceptor ligand such as 2,2′-bipyridine; 2,2′:6′,2′′-terpyridine; triphenylphosphine; and 2,2′-phenylpyridine or diethylphenylphosphine.
- the supromolecular complex may be dissolved or dispersed in a carrier.
- the supramolecular complex in the composition may be [(2,2′-bipyridine) 2 Ru(2-pyridyl) pyrazine)RhCl 2 (2-pyridyl)pyrazine)Ru(2,2′-bipyridine) 2 ](PF 6 ) 5 ; [(2,2′-bipyridine) 2 Os(2,3-bis (2-pyridyl)pyrazine)RhCl 2 (2,3-bis(2-pyridyl)pyrazine)Os(2,2′-bipyridine) 2 ](PF 6 ) 5 ; [(2,2′:6′,2′′-terpyridine) RuCl(2,3-bis(2-pyridyl)pyrazine)RhCl 2 (2,3-bis(2-pyridyl)pyrazine)RuCl(2,2′:6′,2′′-terpyridine)](PF 6 ) 3 ; or [(2,2′:6′,2
- the at least one metal to ligand charge transfer (MLCT) light absorbing metal may be ruthenium(II), osmium(III), rhenium(I), iron(II) or platinum(II).
- the at least one bridging ⁇ -acceptor ligand may be 2,3-bis(2-pyridyl)pyrazine; 2,2′-bipyridimidine; 2,3-bis(2-pyridyl)quinoxaline; or 2,3,5,6,-tetrakis(2-pyridyl)pyrazine.
- the electron acceptor metal may be rhodium(III), platinum(IV), cobalt(III), or iridium(III).
- the supramolecular complex may further comprises at least one terminal n-acceptor ligand such as 2,2′-bipyridine; 2,2′:6′,2′′-terpyridine; triphenylphosphine; and 2,2′-phenylpyridine and diethylphenylphosphine.
- the light may be visible light.
- the supramolecular complex may be [(2,2′-bipyridine) 2 Ru(2-pyridyl) pyrazine)RhCl 2 (2-pyridyl)pyrazine)Ru(2,2′-bipyridine) 2 ](PF 6 ) 5 ; [(2,2′-bipyridine) 2 Os(2,3-bis(2-pyridyl)pyrazine)RhCl 2 (2,3-bis(2-pyridyl)pyrazine)Os(2,2′-bipyridine) 2 ](PF 6 ) 5 ; [(2,2′:6′,2′′-terpyridine) RuCl(2,3-bis(2-pyridyl)pyrazine)RhCl 2 (2,3-bis(2-pyridyl)pyrazine)RuCl(2,2′:6′,2′′-terpyridine)](PF 6 ) 3 ; or [(2,2′:6′,2′′-ter
- the invention further provides a method for decreasing the replication of hyperproliferating cells.
- the method comprises the steps of delivering to said hyperproliferating cells a supramolecular complex which contains at least one metal to ligand charge transfer (MLCT) light absorbing metal; at least one bridging ⁇ -acceptor ligand; and an electron acceptor metal, followed by the step of inducing the production of a metal-to-metal charge transfer state within the supramolecular complex by the application of light, thereby causing a decrease in replication of the hyperproliferating cells.
- MLCT metal to ligand charge transfer
- FIG. 1A-C Molecular structure of A, dpp; B, bpm; and C, tpy.
- FIG. 2 Schematic of building-block synthesis of [ ⁇ (tpy)RuCl(bpm) ⁇ 2 RhCl 2 ] 3+ .
- FIGS. 3A and B A, Orbital Energy Diagram for [ ⁇ (tpy)RuCl(bpm) ⁇ 2 RhCl 2 ] 3+ and [ ⁇ (bpy) 2 Ru(bpm) ⁇ 2 RhCl 2 ] 5+ ;
- B Orbital Energy Diagram for [ ⁇ (tpy)RuCl(dpp) ⁇ 2 RhCl 2 ] 3+ and [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2 RhCl 2 ] 5+ .
- FIG. 5 Electrochemical Mechanism for the Ru, Rh, Ru Triads.
- FIG. 8 Electronic absorption spectra for [ ⁇ (bpy) 2 Ru(bpm) ⁇ 2 RhCl 2 ] 5+ (s), [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2 RhCl 2 ] 5+ ( - - - ), and [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2 IrCl 2 ] 5+ ( . . . ) in doubly distilled water, ddH 2 O.
- Lane 1 is the ⁇ molecular weight standard
- lane 2 is the control linearized DNA (cut with HindIII) with no metal present
- lane 3 is the control circular DNA with no metal present
- lane 4 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex incubated at 37° C.
- FIG. 12A-C DNA Photocleavage by Various Supramolecular Metallic Complexes. Schematic representation of analysis of cleavage patterns by gel electrophoresis.
- Lane 1 is the ⁇ molecular weight standard
- Lane 2 is a plasmid control
- Lane 3 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex incubated at 37° C. for 20 minutes
- Lane 4 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex photolyzed at >475 nm for 20 minutes.
- Lane 1 is the ⁇ molecular weight standard
- Lane 2 is a plasmid control
- Lane 3 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex incubated at 37° C. for 20 minutes
- Lane 4 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex photolyzed at >475 nm for 20 minutes.
- Lane 1 is the ⁇ molecular weight standard
- Lane 2 is a plasmid control
- Lane 3 is the plasmid alone photolyzed ⁇ >475 nm for 15 mins
- Lane 4 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex incubated at 37° C. for 15 minutes
- Lane 5 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex photolyzed at >475 nm for 15 minutes.
- the present invention provides novel metallic DNA cleaving agents that exhibit unique supramolecular architecture.
- the agents are supramolecular metal complexes in which a novel type of excitation is used.
- charge is transferred from one metal to another to generate a metal-to-metal charge transfer state, a unique type of excited state for application to photoactivated DNA cleavage.
- the complexes are able to cleave DNA as a direct result of the molecular design which localizes the highest occupied molecular orbital on at least one charge transfer light absorbing metal center, and the lowest unoccupied molecular orbital on a bioactive electron accepting metal center.
- DNA cleaving agents of the present invention do not require oxygen to function. They thus function efficiently in intracellular environments where O 2 levels are low. Also, since these agents do not generate singlet oxygen, incidental damage to healthy tissue due to release of 1 O 2 to the surrounding environment cannot occur.
- the complexes are activated by the application of visible, low energy light, thus precluding unwanted cellular damage (e.g. of healthy tissue) which occurs as a result of the use of high energy light.
- three essential components are coupled: 1) at least one metal to ligand charge transfer (MLCT) light absorbing metal center; 2) a bridging r-acceptor ligand; and 3) an electron acceptor metal center.
- MLCT metal to ligand charge transfer
- the function of the metal to ligand charge transfer light absorber is to produce an initially optically populated metal to ligand charge transfer state.
- Requirements of the bridging n-acceptor ligand are that it must coordinate to both the light absorbing metal and the electron acceptor metal, and possess a ⁇ system capable of being involved in an initial metal to ligand charge transfer excitation.
- the requirement for the electron acceptor metal is that it bind to the bridging ⁇ -acceptor ligand and be energetically capable of accepting an electron from the optically populated MLCT state to produce the reactive metal to metal charge transfer (MMCT) state. Without being bound by theory, it is believed that it is the MMCT state that functions to cleave the DNA to which the complex is bound.
- two metal to ligand charge transfer light absorbers are utilized.
- those of skill in the art will recognize that only one MLCT light absorber need be present in the complex of the present invention. Alternatively, more than two such light absorbers may be incorporated to produce the initially optically populated metal to ligand charge transfer state.
- the exact number and type of MLCT light absorbers used in the supramolecular metallic complexes of the present invention may vary, depending on several factors including but not limited to: the desired excitation wavelength to be employed; the oxidation potential of interest for the metal based highest occupied molecular orbital; the required extinction coefficient for the excitation wavelength; ease of synthesis of the complex; cost and/or availability of components; and the like.
- Suitable metals exist that can function as MLCT light absorbers in the practice of the present invention. Examples include but are not limited to ruthenium(II), osmium(II), rhenium (I), iron(II), platinum(II), etc. In preferred embodiments, two ruthenium(II) or two osmium(II) centers are utilized.
- the complexes of the present invention require the presence of at least one bridging ⁇ -acceptor ligand capable of being involved in an initial metal to ligand charge transfer excitation.
- bridging ligand we mean that, in the supramolecular complex, the ⁇ -acceptor ligand is located or positioned (i.e. bonded, coordinated) between an MLCT light absorber and an electron acceptor metal. Further, if there is more than one MLCT light absorber in the complex, the bridging ⁇ -acceptor ligands will be positioned to attach each light absorbing unit to either another light absorbing unit or directly to the electron accepting metal center.
- the ⁇ -acceptor ligands coordinate or bind to the metal centers via donor atoms.
- donor atoms Those of skill in the art will recognize that many suitable substances exist which contain appropriate donor atoms and may thus function as ⁇ -acceptor ligands in the complexes of the present invention.
- These ⁇ -acceptor ligands fall into two categories, bridging and terminal ligands. Bridging ligands serve to connect metal centers and thus bind to or coordinate two separate metal centers.
- Terminal ligands bind or coordinate to only one metal center and serve to satisfy the needed coordination sphere for such metals and provide a means to tune both light absorbing and redox properties of that metal center.
- substances with: nitrogen donor atoms e.g.
- pyridine- and pyridimidine-containing moieties such as 2,2′-bipyridine (“bpy”); 2,2′:6′,2′′-terpyridine (“tpy”); 2,3-bis(2-pyridyl)pyrazine (“dpp”); and 2,2′-bipyridimidine (“bpm”); 2,3-bis(2-pyridyl)quinoxaline; 2,3,5,6,-tetrakis(2-pyridyl)pyrazine; carbon and nitrogen donor atoms (e.g. 2,2′-phenylpyridine); phosphorus donor atoms (e.g. triphenylphosphine, diethylphenylphosphine); etc.
- the ⁇ -acceptor ligands are bpy, tpy, dpp and bpm.
- ligands include but are not limited to halogens such as Cl and Br, COOH, CO, H 2 O, CH 3 CN, etc.
- the electron acceptor metal is an essential component of this molecular design. Those of skill in the art will recognize that many metals may be used as the electron acceptor metal in the complexes of the present invention. Examples of suitable metals include but are not limited to rhodium(III), platinum(IV), cobalt(III), iridium(III). Any metal that can bind to a bridging ⁇ -acceptor ligand and accept an electron from the optically populated MLCT state to produce the reactive MMCT state may be utilized. In a preferred embodiment of the invention, the electron acceptor metal is rhodium(III). Further, the number of electron acceptor metal centers in the complex may also be varied. Multifunctional systems could be designed that use many electron acceptor sites to enhance the functioning of the system by providing additional bioactive sites within a single molecular architecture.
- the supramolecular architecture of the complexes of the present invention can be varied by changing the identity and number of components of the complex. However, it is necessary to retain the components in sufficiently close location and appropriate orientation to provide the necessary electronic coupling. This coupling is necessary to allow for electron transfer from the initial ⁇ -acceptor ligand, that accepts the charge in the initially populated metal to ligand charge transfer state, to the electron accepting metal center to lead to the formation of the reactive metal to metal charge transfer state. It is also important that component separation and orientation not allow for rapid relaxation of the reactive MMCT state, facilitated by rapid back electron transfer. Those of skill in the art will recognize that the precise distances between components and the orientation of the components will vary from complex to complex, depending on the identity of complex substituents. However, in general the distances will be confined to the multi-atomic or multi-angstrom scale.
- Exemplary forms of the complexes of the invention contain two ruthenium- or osmiun-based light absorbers which are coupled to a biologically active rhodium metal site.
- the light absorbing metal centers are occupied by Ru or Os, and the central electron acceptor metal site is occupied by Rh.
- the invention further provides new compositions of matter:
- the DNA cleaving agents of the present invention may be used for cleavage of DNA in many settings, including but not limited to cleavage of purified or partially purified DNA in laboratory setting for investigational purposes; and for the cleavage of DNA within cells, either ex vivo or in vivo.
- ex vivo uses include cleavage of DNA in cultured cells for any reason, or of cells that have been removed from an individual with the intent of reintroducing the cells into the individual (or another individual) after manipulation of the cells (e.g. purging of tumor cells, genetic engineering of the cells, etc.) and the like.
- Examples of in vivo uses include the cleavage of DNA of cells within an organism, especially unwanted hyperproliferating cells such as tumor or cancer cells (including but are not limited to leukemia cells, ovarian cancer cells, Burkitt's lymphoma cells, breast cancer cells, gastric cancer cells, testicular cancer cells, and the like), and cells associated with psoriasis, warts, macular degeneration and other non-malignant hyperproliferating conditions.
- tumor or cancer cells including but are not limited to leukemia cells, ovarian cancer cells, Burkitt's lymphoma cells, breast cancer cells, gastric cancer cells, testicular cancer cells, and the like
- cells associated with psoriasis, warts, macular degeneration and other non-malignant hyperproliferating conditions including but are not limited to leukemia cells, ovarian cancer cells, Burkitt's lymphoma cells, breast cancer cells, gastric cancer cells, testicular cancer cells, and the like.
- While the method of the present invention is principally intended to thwart replication of hyperproliferating cells, other cellular populations may be targeted as well. For example, cells infected by a pathological agent such as a-virus or bacterium, may also be targeted.
- a pathological agent such as a-virus or bacterium
- Exposure of DNA to the agents of the present invention results in binding of the agents to the DNA and subsequent cleavage of the DNA.
- the cleavage pattern may be random.
- the complexes of the present invention may be purposefully designed to favor binding at particular regions of the DNA and so affect site specific (or at least site-preferential) cleavage.
- the complexes may be designed to bind preferentially to a particular sequence of bases, or to a particular structural motif or location (e.g. to A-, B-, or Z-DNA, or to the major or minor groove). It is also possible to append to this supramolecular structure architecture recognition sites that would lead to site specific cleavage of DNA.
- single stranded DNA sequences can be appended to the complexes to allow recognition of complementary strands and subsequent selective cleavage at the site of metal complex attachment.
- proteins or fragments of proteins that bind selectively to specific regions of a DNA molecule may also be attached, e.g. topoisomerases, gyrases, DNA polymerases, etc. Methods of attaching or appending additional substituents to the complexes of the present invention would be well-known to those of skill in the art, e.g. by substitution of a non-essential ligand such as a terminal ligand.
- the complexes may be used to cleave either double- or single-stranded DNA, as well as DNA-RNA hybrids, and double- or single-stranded RNA.
- the agents of the present invention bind to and cleave DNA within cells for which it is desired to attenuate the ability to replicate.
- the agents of the present invention appear to provide a less drastic mode of treating pathological conditions which result from the hyperproliferation of cells in that the agents appear to cause a cessation of replication without killing the hyperproliferating cells outright. This is an advantage because the immediate killing of, for example, all tumor cells in a tumor mass can have unwanted results for a patient in which the tumor is being treated. If millions of tumor cells are killed outright many or most of the cells undergo lysis, releasing their contents into the environment.
- the present invention provides specificity in attenuating cellular proliferation in that activation of DNA cleavage and subsequent cell damage and/or death will occur only when the cells containing the cleavage agent are exposed to suitable wavelengths of light.
- suitable wavelengths of light for use in the practice of the present invention are dependent on the components of a given supramolecular complex. In general, low energy, visible light is utilized. By “low energy, visible light” we mean light of wavelengths >475 nm. For example, the wavelength used will depend on the complex of interest and its ability to absorb at that wavelength as well as the ability of the wavelength of light to penetrate the applicable biological material. Typically excitation would occur in the region of the intense metal to ligand charge transfer excitation.
- the targeted cells when they are in vivo (i.e. located internally within an organism), they will be exposed to light only when light of an appropriate wavelength is deliberately introduced into the environment, for example, during a studied surgical procedure using, e.g., optical fibers.
- optical fibers are threaded through a catheter or endoscope, allowing for small incisions while delivering a focused beam of light.
- the targeted cells are ex vivo, cells are shielded until light of the wavelength that would activate the photosensitizing agent could be purposefully administered.
- Many companies such as Coherent Medical Group, Coherent Inc., Palo Alto, Calif.), manufacture products specifically designed for the production of narrow wavelengths of light required for medical use.
- gas lasers as well as LEDs are commercially available and capable of producing the requisite light.
- Any appropriate means of illuminating the target cells that results in activation of the photosensitizer molecule within the target cells, so that injury or death of the target cells results, may be utilized in the practice of the present invention.
- methods of illumination see Bellnier, D. et al. 1999. Design and construction of a light-delivery system for photodynamic therapy. Med. Phys. 26: 1552.
- the agents may be coupled to targeting moieties such as antibodies, lectins, targeting fragments such as bacterial toxin molecules or fragments of such molecules, all of which can serve to direct the cleaving agent to the targeted population of cells, and also to promote uptake of the complex by the cell.
- targeting moieties such as antibodies, lectins, targeting fragments such as bacterial toxin molecules or fragments of such molecules, all of which can serve to direct the cleaving agent to the targeted population of cells, and also to promote uptake of the complex by the cell.
- a DNA cleaving agent of the present invention to an antibody specific for an antigen that is expressed on a particular type of tumor cell, the agent can be delivered to the tumor cells of interest. See, for example, U.S. Pat. No. 6,426,400 to Zalutsky (Jul. 30, 2002) and U.S. Pat. No. 6,492,123 to Hollinger et al., (Dec. 10, 2002), the complete contents of which are hereby incorporated by reference.
- DNA cleaving agents of the present invention may be carried out by any of several known methods and will vary from case to case, depending on the particular application. For example, for some laboratory applications, solutions of the agents may be mixed directly with the DNA to be cleaved. For the cleavage of cultured cells (including ex vivo cells) the cleaving agents of the present invention may be added directly to the culture media where they are taken up by the cells. For in vivo applications, those of skill in the art will recognize that many means of administration exist, including but not limited to: direct application of the DNA cleaving agent in a suitable carrier, e.g.
- a cancerous lesion such as a melanoma or other area of exposed hyperproliferating tissue; or by delivery directly into the tumor or other hyperproliferating tissue, e.g. by injection or other type of direct infusion.
- Other means of delivery include systemic delivery. In the case of systemic delivery, many cells will be exposed to and internalize the agents of the present invention. However, only those cells which are later exposed to suitable wavelengths of light will be effected by the presence of the agent by cleavage of their DNA. Residual agent within non-targeted cells will be eliminated from the body over a time period of about two weeks, during which the patient must avoid exposure to wavelengths of light that would activate the agents.
- the agents of the present invention may be administered by any of several suitable means that are well-known to those of skill in the art.
- suitable means for example, intramuscularly, intravenously, intratumorally, orally (e.g. in liquid or tablet/capusular form), via suppositories, via inhalation, and the like.
- the present invention also provides a composition for administration to hyperproliferating cells.
- the composition comprises at least one of the DNA cleaving agents and a suitable carrier, e.g. a suitable physiological carrier for in vivo administration, e.g. saline.
- a suitable carrier e.g. a suitable physiological carrier for in vivo administration, e.g. saline.
- the composition may be administered in any of a variety of suitable forms, including forms that include additional components such as buffers, stabilizers, nutrients, anti-oxidants, flavorings, colorants, and the like, which are appropriate to a means of administration. Those of skill in the art will recognize that the exact form will vary from application to application.
- the compounds can be administered in the pure form or in a pharmaceutically acceptable formulation including suitable elixirs, binders, and the like or as pharmaceutically acceptable salts or other derivatives.
- pharmaceutically acceptable formulations and salts include liquid and solid materials conventionally utilized to prepare injectable dosage forms and solid dosage forms such as tablets and capsules.
- Water may be used for the preparation of injectable compositions which may also include conventional buffers and agents to render the injectable composition isotonic.
- Solid diluents and excipients include lactose, starch, conventional disintegrating agents, coatings and the like. Preservatives such as methyl paraben or benzalkium chloride may also be used.
- the active composition will consist of 1-99% of the composition and the vehicular “carrier” will constitute 1-99% of the composition.
- the dosage, frequency and liming of administration will vary from case to case and will depend on factors such as the particular application, the nature and stage of a condition resulting from hyperproliferation of cells (e.g. size and location of a malignant or non-malignant tumor), characteristics of the patient (e.g. overall health, age, weight, gender and the like), and other factors such as ancillary treatments (chemotherapy, radiotherapy, and the like).
- the details of administration are best determined by a skilled practitioner such as a physician. Further, the details of administration are normally worked out during clinical trials.
- the approximate dosage range will preferably be from about 0.1 to 10 mg of agent per kg of weight, and more preferably from about 0.25 to 1.0 mg/kg.
- the amount of agent to be administered is preferably in the range of about 0.1-50 ⁇ g per about 0.1-50 ⁇ g of DNA, and more preferably, in the range of about 1-10 ⁇ g per about 1-10 ⁇ g of DNA.
- the agent will be administered about 1 to 24 hours prior to exposure to a suitable light source, and preferably from about 1 to 4 hours prior to exposure to the light source.
- the dose or frequency of illumination of the target cells will vary from case to case, but will generally be in the range of 25-200 J/cm 2 light dose, 25-200 mW/cm 2 fluence rate (see Ochsner, M. 1997. Photodynamic Therapy: the Clinical Perspective. Review on applications for control of diverse tumours and non-tumour diseases. Drug Res., 47:1185-1194).
- BL polyazine bridging ligands
- the BL serves to bring the metal centers into close proximity and creates a pathway for energy or electron transfer.
- the commonly used bridging ligand 2,3-bis(2-pyridyl)pyrazine (dpp) ( FIG. 1A ) binds to two metal centers through a pyridyl and a pyrazine nitrogen, acting as an AB chelate, resulting in a mixture of stereoisomers not typically separated.
- dpp 2,3-bis(2-pyridyl)pyrazine
- FIG. 1B Another BL which performs the same function but has not received as much attention is 2,2′-bipyrimidine (bpm) ( FIG. 1B ), which binds to two metal centers through two equivalent nitrogens eliminating the stereoisomers associated with the AB chelates. 11,13,16,17
- terminal ligands typically bpy
- TL terminal ligands
- Another TL used in supramolecular complexes is 2,2′:6′,2′′-terpyridine (tpy) ( FIG. 1C ).
- [Ru(tpy) 2 ] 2+ has a short-lived excited state
- the tpy ligand brings the advantage of eliminating the ⁇ and ⁇ isomeric mixtures associated with the tris-bidentate metal centers giving some stereochemical control in supramolecular complexes. Long lived excited states are observed for many ruthenium tpy complexes incorporating polyazine bridging ligands. 21-30
- a trimetallic structural motif would be an interesting framework to exploit the electron acceptor properties of the rhodium metal center. This requires the development of synthetic methods and the ability to modulate orbital energies in a supramolecular architecture.
- the trimetallic complexes [ ⁇ (tpy)RuCl(dpp) ⁇ 2 RhCl 2 ](PF 6 ) 3 and [ ⁇ (tpy)RuCl(bpm) ⁇ 2 RhCl 2 ](PF 6 ) 3 have been synthesized and characterized by FAB mass spectral analysis, electronic absorption spectroscopy, electrochemistry, and spectroelectrochemistry.
- 2,2′:6′,6′′-Terpyridine (tpy) (GFS chemicals), ruthenium(III) chloride hydrate, rhodium trichloride hydrate, and 2,2′-bipyrimidine (bpm) (Alfa), triethylamine (Acros), 2,3-bis(2-pyridyl)-pyrazine (dpp) (Aldrich), (80-200 mesh) adsorption alumina (Fisher), and spectroquality grade acetonitrile and toluene (Burdick and Jackson) were used as received.
- Tetrabutylammonium hexafluorophosphate Bu 4 NPF 6 (used as supporting electrolyte for electrochemistry experiments) was prepared by the aqueous metathesis of tetrabutylammonium bromide (Aldrich) with potassium hexafluorophosphate (Aldrich). After several recrystallizations from ethanol the white crystals were dried under vacuum and stored in a vacuum desiccator. Elemental analysis was performed by Galbraith Laboratories, Inc., Knoxville, Tenn.
- Cyclic voltammograms were recorded using a one-compartment three-electrode cell, Bioanalytical Systems (BAS), equipped with a platinum wire auxiliary electrode.
- the working electrode was a 1.9 mm diameter glassy carbon disk from BAS. Potentials were referenced to a Ag/AgCl electrode (0.29 V vs NHE), which was calibrated against the FeCp 2 /FeCp 2 + redox couple (0.67 V vs NHE).48
- the supporting electrolyte was 0.1 M Bu 4 NPF 6 , and the measurements were made in Burdick and Jackson UV-grade acetonitrile, which was dried over 3 ⁇ molecular sieves.
- Spectroelectrochemical measurements were conducted according to a previously described method using a locally constructed H-cell which uses a quartz cuvette as the working compartment.49
- the working and auxiliary compartments were separated by a fine porous glass frit.
- the working electrode and auxiliary electrodes were high surface area platinum mesh, and the reference electrode was Ag/AgCl (0.29 V vs NHE).
- the measurements were made in 0.1 M Bu 4 NPF 6 /acetonitrile solutions that were 2 ⁇ 10 ⁇ 5 M metal complex.
- the electrolysis potential was controlled by a BAS 100 W electrochemical analyzer.
- FAB mass spectral analysis was performed by M-Scan Incorporated, West Chester, Pa., on a VG Analytical ZAB 2-SE high-field mass spectrometer using m-nitrobenzyl alcohol as a matrix.
- the trimetallic gave very nice FABMS patterns with sequential loss of each PF 6 ion being observed.
- the fragmentation pattern was consistent with the proposed molecular structure.
- the supramolecular complexes [ ⁇ (tpy)RuCl(dpp) ⁇ 2 RhCl 2 ](PF 6 ) 3 and [ ⁇ (tpy)RuCl(bpm) ⁇ 2 RhCl 2 ](PF 6 ) 3 were prepared in good yields under mild conditions using a building-block approach. It is this method that allows for easy variation of structural components within this structural motif.
- the tpy is first bound to ruthenium followed by BL attachment. 45,46
- FIG. 2 The synthesis of [ ⁇ (tpy)RuCl(bpm) ⁇ 2 RhCl 2 ](PF 6 ) 3 by this method is illustrated in FIG. 2 .
- This method of binding the bpm or dpp ligand to the ruthenium metal center first and then binding to the rhodium metal center yields clean reactions with easily purified products.
- the use of excess rhodium(III) trichloride hydrate ensures that most of the monometallic precursor is reacted.
- the major product in each case is the desired trimetallic.
- the excess rhodium(III) trichloride is easily removed by aqueous washings of the precipitated hexafluorophosphate salt of the trimetallic complex.
- dpp as a bridging ligand leads to cis and trans type stereoisomers, around the Ru which are not detectable by cyclic voltammetry or electronic absorption spectroscopy. 46,47 Utilization of the symmetric bridging ligand bpm eliminates the cis/trans type stereoisomers present in the dpp synthons.
- Trimetallic complexes of the form [ ⁇ (bpy) 2 Ru(CL) ⁇ 2 RhCl 2 ] 5+ are characterized by reversible ruthenium oxidations, irreversible rhodium reductions, and reversible ligand reductions, with the BLs (dpp or bpm) being reduced prior to the bpy ligands. 32,34 They display a Ru(d ⁇ ) HOMO. The LUMO is localized on Rh(d ⁇ *) for dpp and bpm( ⁇ *) for the bpm bridged system.
- a reversible redox couple at 1.12 V is observed in the positive potential region.
- This redox couple is attributed to two overlapping Ru II/III oxidations. These LAs are largely electronically uncoupled, allowing them to function independently. 31,34
- the Ru II/III couples occur 480 mV less positive in the [ ⁇ (tpy)RuCl(dpp) ⁇ 2 RhCl 2 ] 3+ systems relative to the bpy systems, resulting from the chloride coordination on the Ru centers in the tpy systems. Reductively an irreversible peak is observed at ⁇ 0.47 V. This couple results from the overlapping reduction of the Rh(III) to Rh(II) and then to Rh(1).
- Rh(bpy) 2 Cl 2 Similar behavior is reported by DeArmond for the [Rh(bpy) 2 Cl 2 ] + . 50 Reduction of the Rh(III) to Rh(I) should be followed by conversion of the formally d 6 pseudocathedral Rh(III) to a square planar d 8 Rh(I). This occurs by chloride loss as evidenced by the presence of free chloride seen in anodic scans that follow cathodic scans through the Rh III/I couple. No evidence of Rh(I) reoxidation is seen in multiple scan experiments.
- the proposed electrochemical mechanism is shown in FIG. 5 .
- the cyclic voltammogram of [ ⁇ (tpy)RuCl(bpm) ⁇ 2 RhCl 2 ] 3+ in 0.4 M Bu 4 NPF 6 /CH 3 CN solution is illustrated in FIG. 4B and summarized in Table 1.
- Two closely spaced irreversible reductions at ⁇ 0.26 and ⁇ 0.38 V in FIG. 4B are assigned as sequential one-electron reductions of the rhodium center, Rh III/II and Rh II/I .
- the new bpm-based trimetallic complex [ ⁇ (tpy)RuCl(bpm) ⁇ 2 RhCl 2 ] 3+ displays a Rh(d ⁇ *) LUMO in marked contrast to the bpm( ⁇ *) LUMO in [ ⁇ (bpy) 2 Ru(bpm) ⁇ 2 RhCl 2 ] 5+ .
- the redox chemistry of [ ⁇ (bpy) 2 Ru(bpm) ⁇ 2 RhCl 2 ] 5+ is characterized by two reversible one-electron bpm ⁇ based reductions at ⁇ 0.13 and ⁇ 0.26 V followed by the irreversible reduction of the rhodium center, Rh III/I , at ⁇ 0.78 V.
- the electronic absorption spectra for [ ⁇ (tpy)RuCl(dpp) ⁇ 2 RhCl 2 ] 3 and [ ⁇ (tpy)RuCl(bpm) ⁇ 2 RhCl 2 ] 3+ in acetonitrile are characterized by high-energy tpy and BL ( ⁇ to ⁇ *) transitions, with tpy bands at 274 nm and 314 nm. A shoulder observed at ca. 340 or 360 nm is attributed to the BL ( ⁇ to ⁇ *) transition for dpp and bpm, respectively. 31b Significant spectral differences between these two trimetallics becomes apparent when the visible regions of the spectra are compared.
- Spectroelectrochemistry was used to study the electronic absorption spectroscopy and cyclic voltammetry of the title trimetallics.
- the spectroelectrochemistry of [ ⁇ (tpy)RuCl(dpp) ⁇ 2 RhCl 2 ] 3+ and [ ⁇ (tpy)RuCl(bpm) ⁇ 2 RhCl 2 ] 3+ is shown in FIGS. 6A and 6B .
- the two-electron oxidation of [ ⁇ (tpy)RuCl(dpp) ⁇ 2 RhCl 2 ] 3+ is greater than 95% reversible.
- This example demonstrates that the nature of the lowest lying transition is metal to ligand charge transfer in character. Additionally, this example demonstrates the Rh-based nature of the LUMO allowing this Rh metal to function as an electron acceptor within this structural motif. This established the metal to metal nature of the lowest lying excited state of these complexes.
- photosensitizers that absorb low energy light, are tunable, and function in the absence of molecular oxygen is of interest. Oxygen independent systems function under conditions of low oxygen content and often have a different mechanism of photocleavage. 16 A photosensitizer which can be excited with low energy light can avoid the base damage induced by UV light. 21,22
- Rhodium and ruthenium complexes photocleave DNA.
- Photolysis at 310 nm of rhodium(III) complexes of phi (9,10-phenanthrenequinone diimine) leads to hydrogen abstraction from the 3′-carbon of deoxyribose, leading to DNA cleavage.
- 23 Cleavage selectivity can be modulated by ancillary 24 and active 25 ligand variation or by tethering to DNA.
- Rh(phi) 2 (phen)] 3+ has recently been shown to stabilize duplex DNA inhibiting transcription.
- Trimetallic complexes coupling light absorbing ruthenium centers to reactive metal centers have been of interest.
- MLCT metal to ligand charge transfer
- the Ir and Rh analogues [( ⁇ (bpy) 2 Ru(dpp) ⁇ 2 MCl 2 ] 5+ , have spectroscopy that is virtually identical owing to their similar supramolecular structure and the dominance of the Ru light absorbers on the spectroscopic properties of these systems.
- the electrochemical properties vary with BL and M for [ ⁇ (bpy) 2 Ru(BL) ⁇ 2 MCl 2 ] 5+ , summarized in Table 3.
- the complexes exhibit a single reversible oxidation wave in the anodic region (1.56 and 1.70 V vs Ag/AgCl) attributed to the overlapping Ru III/II redox couple for the two equivalent Ru centers.
- Rh(d ⁇ *) LUMO in the [ ⁇ (bpy) 2 Ru(bpm) ⁇ 2 RhCl 2 ] 5+ system allowed us to use this as a very similar supramolecular architecture control system with a lowest lying MLCT state.
- pUC18 and pBluescript were used to probe pbotocleavage of DNA by gel electrophoresis.
- 14,26,41,42 pUC18 plasmid is 2686 bp (Bayou Biolabs).
- FIG. 10 shows imaged ethidium bromide stained agarose gels that reveal that the excited state of [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2 RhCl 2 ] 5+ photocleaves DNA.
- Lane 1 FIG. 10 a
- Lane 2 FIG. 10 a
- pUC18 plasmid is found mostly as the supercoiled state (form I) with a small amount of nicked, circular DNA (form II).
- ⁇ irr ⁇ 475 nm When irradiated ( ⁇ irr ⁇ 475 nm) for 10 min, the plasmid alone (lane 3) does not cleave. 42 When incubated at 37° C.
- FIG. 10 c shows a similar cleavage of pBluescript plasmid using a narrow band excitation. These cleavage reactions are also observed in the presence of molecular oxygen.
- the bpm analogue [ ⁇ (bpy) 2 Ru(bpm) ⁇ 2RhCl 2 ] 5+ and the Ir analogue [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2 IrCl 2 ] 5+ , which contain inaccessible Rh(d ⁇ *) and Ir(d ⁇ *) orbitals, 39,40 were studied for their ability to photocleave DNA.
- the Ir analogue has nearly identical electronic absorption spectroscopy to that of the Rh complex. This allows it to function well as a control system possessing a lowest lying MLCT state. The results of this study are shown in FIG. 10 b .
- Lanes 1 and 2 are the plasmid controls. Lanes 3 and 5 reveal that when the plasmid is incubated at 37° C. in the presence of [ ⁇ (bpy) 2 Ru(bpm) ⁇ 2 RhCl 2 ] 5+ or [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2 IrCl 2 ] 5+ , respectively, at a 1:5 metal complex to base pair ratio, no DNA cleavage occurs. Similar solutions irradiated ( ⁇ irr ⁇ 475 nm) for 10 min (lanes 4 and 6), in the absence of molecular oxygen, also do not result in DNA cleavage. Similar studies in the presence of oxygen also do not result in DNA cleavage.
- the line with square symbols ( ⁇ ) shows the results obtained when Vero cells are incubated in the dark with various concentrations of [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2 RhCl 2 ](PF 6 ) 5 .
- exposure to [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2 RhCl 2 ](PF 6 ) 5 alone (i.e. without illumination) did not impact replication.
- the concentration dependence of photoinduced inhibition of cell replication by the supramolecular complex [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2 RhCl 2 ]Cl 5 is shown in FIG. 11B .
- the line with circular symbols shows the impact on Vero cell growth of the incubation of the cells in the dark with the indicated concentrations of [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2RhCl 2 ]Cl 5 .
- the line with square symbols shows the growth of Vero cells incubated with the same concentrations of [ ⁇ (bpy) 2 Ru(dpp) ⁇ 2 RhCl 2 ]Cl 5 , and subsequent irradiation for 10 minutes at ⁇ >475 nm. As can be seen, irradiation at ⁇ >475 nm greatly inhibits the ability of Vero cells to replicate. This is likely due to photoinduced death of the irradiated cells.
- each complex displayed the ability to efficiently cleave DNA upon activation by low energy, visible light.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides supramolecular metal complexes as DNA cleaving agents. In the complexes, charge is transferred from one light absorbing metal (e.g. Ru or Os) to an electron accepting metal (e.g. Rh) via a bridging π-acceptor ligand. A bioactive metal-to-metal charge transfer state capable of cleaving DNA is thus generated. The complexes function when irradiated with low energy visible light with or without molecular oxygen.
Description
This invention was made using funds from a grant from the National Science Foundation having grant number CHE-9632713. The government may have certain rights in this invention.
1. Field of the Invention
The invention generally relates to photodynamic therapy agents. In particular, the invention provides tunable supramolecular metallic complexes which can be activated to cleave DNA by low energy light and in the absence of O2.
2. Background of the Invention
Photodynamic therapy (PDT) is currently gaining acceptance for the treatment of hyperproliferating tissues such as cancers and non-malignant lesions. Significant emphasis has been placed on developing photochemical reagents capable of cleaving DNA for such purposes. Photochemical approaches are of particular interest as they offer reaction control and can be highly targeted.
One popular approach in the design of photodynamic agents involves the sensitization of molecular oxygen. Typically, such agents absorb light energy and transfer that energy to molecular oxygen to generate a reactive singlet oxygen state 1O2. The 1O2 state is highly reactive and, in an intracellular environment, 1O2 randomly reacts with and damages biomolecules and subcellular components, leading to potentially lethal damage to the cell. However, the use of such agents has several drawbacks. For example, the wavelengths of light that must be used to activate this type of photodynamic agent are short wavelength/high energy and cause extensive damage to healthy tissue adjacent to the targeted, hyperproliferating cells. The targeted cell may lyse, releasing 1O2 into the immediate environment where it continues to react randomly with and damage healthy tissue in the area. Further, such agents require the presence of oxygen, the level of which is relatively low in an intracellular environment. Finally, there is an overall lack of flexibility in the design of such agents.
It is thus of interest to develop photosensitizing agents for photodynamic therapy with alternative mechanisms of action. In particular, it would be of benefit to have available photosensitizing agents that absorb and are activated by low energy light. The use of photosensitizing agents that absorb low energy light is less likely to cause unwanted collateral damage to non-targeted cells in a photodynamic therapy setting. In addition, it would be of benefit to have available photosensitizing agents that function efficiently in the absence of molecular oxygen as such agents would be particularly suitable for intracelluar use. Further, it would be highly desirable to have available tunable photosensitizing agents, i.e. photosensitizing agents with a flexible architectural motif that can be readily adjusted or tailored for use in specific applications.
The present invention provides novel metal-based DNA cleaving agents. The agents are supramolecular metallic complexes containing at least one metal to ligand charge transfer (MLCT) light absorbing metal, at least one bridging T-acceptor ligand, and an electron acceptor metal. The complexes are capable of effecting the cleavage of DNA upon exposure to low energy visible light, and do so in the absence of oxygen.
The invention provides new compositions of matter of the forms:
1) [(2,2′-bipyridine)2Os(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl)pyrazine) Os(2,2′-bipyridine)2](X)5, where X is a counterion selected from the group consisting of PF6 −, Cl−, Br−, CF3SO3 − and BF4 −.
2) [(2,2′:6′,2″-terpyridine)RuCl(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl) pyrazine)RuCl(2,2′:6′,2″-terpyridine)](X)3, where X is a counterion selected from the group consisting of PF6 −, Cl−, Br−, CF3SO3 − and BF4 −; and
3) [(2,2′:6′,2″-terpyridine)RuCl(2,2′-bipyridimidine)RhCl2(2,2′-bipyridimidine)RuCl(2,2′:6′,2″-terpyridine)](X)3, where X is a counterion selected from the group consisting of PF6 −, Cl−, Br−, CF3SO3 − and BF4 −. The invention also provides composition, comprising at least one of the above compounds dissolved or dispersed in a carrier.
The invention further provides a method for cleaving DNA. The method includes the steps of combining the DNA with a supramolecular complex. The complex contains at least one metal to ligand charge transfer (MLCT) light absorbing metal, at least one bridging i-acceptor ligand, and an electron acceptor metal. The step of combining is carried out under conditions that allow the supramolecular complex to bind to the DNA, and the supramolecular complex is present in sufficient quantity to cleave said DNA. The second step of the method is exposing the DNA to light or radiant energy in an amount sufficient to activate the supramolecular complex to cleave the DNA. The metal to ligand charge transfer (MLCT) light absorbing metal may be, for example, ruthenium(II), osmium(III), rhenium(I), iron(II) or platinum(II). The bridging π-acceptor ligand may be, for example, 2,3-bis(2-pyridyl)pyrazine; 2,2′-bipyridimidine; 2,3-bis(2-pyridyl)quinoxaline; or 2,3,5,6,-tetrakis(2-pyridyl)pyrazine. The electron acceptor metal may be, for example, rhodium(III), platinum(IV), cobalt(III), or iridium(III). The supramolecular complex may further include at least one terminal π-acceptor ligand, in which case the terminal π-acceptor ligand may be, for example, 2,2′-bipyridine; 2,2′:6′,2″-terpyridine; triphenylphosphine; and 2,2′-phenylpyridine or diethylphenylphosphine. In a preferred embodiment, the light used to activate the complex is visible light.
The supramolecular complex utilized in the method may be, for example, [(2,2′-bipyridine)2 Ru(2-pyridyl)pyrazine)RhCl2(2-pyridyl)pyrazine)Ru(2,2′-bipyridine)2](PF6)5; [(2,2′-bipyridine)2Os(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl)pyrazine)Os(2,2′-bipyridine)2](PF6)5; [(2,2′:6′,2″-terpyridine)RuCl(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis (2-pyridyl)pyrazine)RuCl(2,2′:6′,2″-terpyridine)](PF6)3; or [(2,2′:6′,2″-terpyridine)RuCl(2,2′-bipyridimidine)RhCl2(2,2′-bipyridimidine)RuCl(2,2′:6′,2″-terpyridine)](PF6)3′ In addition, the combining step of the method may occur within a hyperproliferating cell.
The invention also provides a composition for effecting the cleavage of DNA in hyperproliferating cells. The composition contains a supramolecular complex comprising at least one metal to ligand charge transfer (MLCT) light absorbing metal; at least one bridging n-acceptor ligand; and an electron acceptor metal. The metal to ligand charge transfer (MLCT) light absorbing metal may be ruthenium(II), osmium(III), rhenium(I), iron(II) or platinum(II). The bridging π-acceptor ligand may be 2,3-bis(2-pyridyl)pyrazine; 2,2′-bipyridimidine; 2,3-bis(2-pyridyl) quinoxaline; or 2,3,5,6,-tetrakis(2-pyridyl)pyrazine. The electron acceptor metal may be rhodium(III), platinum(IV), cobalt(III), or iridium(III). The supramolecular complex may further comprises at least one terminal π-acceptor ligand such as 2,2′-bipyridine; 2,2′:6′,2″-terpyridine; triphenylphosphine; and 2,2′-phenylpyridine or diethylphenylphosphine. The supromolecular complex may be dissolved or dispersed in a carrier.
The supramolecular complex in the composition may be [(2,2′-bipyridine)2 Ru(2-pyridyl) pyrazine)RhCl2(2-pyridyl)pyrazine)Ru(2,2′-bipyridine)2](PF6)5; [(2,2′-bipyridine)2Os(2,3-bis (2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl)pyrazine)Os(2,2′-bipyridine)2](PF6)5; [(2,2′:6′,2″-terpyridine) RuCl(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl)pyrazine)RuCl(2,2′:6′,2″-terpyridine)](PF6)3; or [(2,2′:6′,2″-terpyridine)RuCl(2,2′-bipyridimidine)RhCl2(2,2′-bipyridimidine)RuCl(2,2′:6′,2″-terpyridine)](PF6)3.
The invention further provides a method for decreasing the replication of hyperproliferating cells. The method includes the steps of delivering a supramolecular complex to the cells, the complex containing at least one metal to ligand charge transfer (MLCT) light absorbing metal; at least one bridging π-acceptor ligand; and an electron acceptor metal. The method further includes the step of applying light or radiant energy to the hyperproliferating cells. The step of applying light to the hyperproliferating cells induces the production of a metal-to-metal charge transfer state within the supramolecular complex. The metal-to-metal charge transfer state mediates the cleavage of DNA of the hyperproliferating cells, thereby causing a decrease in the replication of the hyperproliferating cells.
In the method, the at least one metal to ligand charge transfer (MLCT) light absorbing metal may be ruthenium(II), osmium(III), rhenium(I), iron(II) or platinum(II). The at least one bridging π-acceptor ligand may be 2,3-bis(2-pyridyl)pyrazine; 2,2′-bipyridimidine; 2,3-bis(2-pyridyl)quinoxaline; or 2,3,5,6,-tetrakis(2-pyridyl)pyrazine. The electron acceptor metal may be rhodium(III), platinum(IV), cobalt(III), or iridium(III). The supramolecular complex may further comprises at least one terminal n-acceptor ligand such as 2,2′-bipyridine; 2,2′:6′,2″-terpyridine; triphenylphosphine; and 2,2′-phenylpyridine and diethylphenylphosphine. The light may be visible light. The supramolecular complex may be [(2,2′-bipyridine)2 Ru(2-pyridyl) pyrazine)RhCl2(2-pyridyl)pyrazine)Ru(2,2′-bipyridine)2](PF6)5; [(2,2′-bipyridine)2Os(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl)pyrazine)Os(2,2′-bipyridine)2](PF6)5; [(2,2′:6′,2″-terpyridine) RuCl(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2-pyridyl)pyrazine)RuCl(2,2′:6′,2″-terpyridine)](PF6)3; or [(2,2′:6′,2″-terpyridine)RuCl(2,2′-bipyridimidine)RhCl2(2,2′-bipyridimidine)RuCl (2,2′:6′,2″-terpyridine)](PF6)3. The hyperproliferating cells may be cancer cells.
The invention further provides a method for decreasing the replication of hyperproliferating cells. The method comprises the steps of delivering to said hyperproliferating cells a supramolecular complex which contains at least one metal to ligand charge transfer (MLCT) light absorbing metal; at least one bridging π-acceptor ligand; and an electron acceptor metal, followed by the step of inducing the production of a metal-to-metal charge transfer state within the supramolecular complex by the application of light, thereby causing a decrease in replication of the hyperproliferating cells.
A, DNA Photocleavage of pUC18 using [{(bpy)2Os(dpp)}2RhCl2](PF6)5: Lane 1 is the λ molecular weight standard, Lane 2 is a plasmid control, Lane 3 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex incubated at 37° C. for 20 minutes, Lane 4 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex photolyzed at >475 nm for 20 minutes.
B, DNA Photocleavage of pBluescript using [{(tpy)RuCl(dpp)}2RhCl2](PF6)3: Lane 1 is the λ molecular weight standard, Lane 2 is a plasmid control, Lane 3 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex incubated at 37° C. for 20 minutes, Lane 4 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex photolyzed at >475 nm for 20 minutes.
C, DNA Photocleavage of pUC18 using [{(tpy)RuCl(bpm)}2RhCl2](PF6)3: Lane 1 is the λ molecular weight standard, Lane 2 is a plasmid control, Lane 3 is the plasmid alone photolyzed λ>475 nm for 15 mins, Lane 4 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex incubated at 37° C. for 15 minutes, Lane 5 is a 1:5 metal complex/base pair mixture of the plasmid with the metal complex photolyzed at >475 nm for 15 minutes.
The present invention provides novel metallic DNA cleaving agents that exhibit unique supramolecular architecture. The agents are supramolecular metal complexes in which a novel type of excitation is used. In the complexes, charge is transferred from one metal to another to generate a metal-to-metal charge transfer state, a unique type of excited state for application to photoactivated DNA cleavage. The complexes are able to cleave DNA as a direct result of the molecular design which localizes the highest occupied molecular orbital on at least one charge transfer light absorbing metal center, and the lowest unoccupied molecular orbital on a bioactive electron accepting metal center. This general molecular architectural scheme allows great flexibility in terms of the design of DNA cleaving complexes since many different substances may function as components of the system. Further, in contrast to most known photodynamic therapy agents, the DNA cleaving agents of the present invention do not require oxygen to function. They thus function efficiently in intracellular environments where O2 levels are low. Also, since these agents do not generate singlet oxygen, incidental damage to healthy tissue due to release of 1O2 to the surrounding environment cannot occur. In addition, the complexes are activated by the application of visible, low energy light, thus precluding unwanted cellular damage (e.g. of healthy tissue) which occurs as a result of the use of high energy light.
In the agents, three essential components are coupled: 1) at least one metal to ligand charge transfer (MLCT) light absorbing metal center; 2) a bridging r-acceptor ligand; and 3) an electron acceptor metal center. The function of the metal to ligand charge transfer light absorber is to produce an initially optically populated metal to ligand charge transfer state. Requirements of the bridging n-acceptor ligand are that it must coordinate to both the light absorbing metal and the electron acceptor metal, and possess a π system capable of being involved in an initial metal to ligand charge transfer excitation. The requirement for the electron acceptor metal is that it bind to the bridging π-acceptor ligand and be energetically capable of accepting an electron from the optically populated MLCT state to produce the reactive metal to metal charge transfer (MMCT) state. Without being bound by theory, it is believed that it is the MMCT state that functions to cleave the DNA to which the complex is bound.
In one embodiment of the present invention, two metal to ligand charge transfer light absorbers are utilized. However, those of skill in the art will recognize that only one MLCT light absorber need be present in the complex of the present invention. Alternatively, more than two such light absorbers may be incorporated to produce the initially optically populated metal to ligand charge transfer state. The exact number and type of MLCT light absorbers used in the supramolecular metallic complexes of the present invention may vary, depending on several factors including but not limited to: the desired excitation wavelength to be employed; the oxidation potential of interest for the metal based highest occupied molecular orbital; the required extinction coefficient for the excitation wavelength; ease of synthesis of the complex; cost and/or availability of components; and the like. Any suitable number of MLCT light absorbers may be used so long as within the complex an initial optically populated MLCT state is produced upon exposure to light or radiant energy, and which can be relayed to a suitable bridging ligand for transfer to an electron acceptor metal. In preferred embodiments, the number of MLCT light absorbers will range from 1 to about 14, and preferably from 1 to about 5, and more preferably from 1 to about 3. In one embodiment of the invention, two MLCT light absorbers are utilized.
Those of skill in the art will recognize that many suitable metals exist that can function as MLCT light absorbers in the practice of the present invention. Examples include but are not limited to ruthenium(II), osmium(II), rhenium (I), iron(II), platinum(II), etc. In preferred embodiments, two ruthenium(II) or two osmium(II) centers are utilized.
The complexes of the present invention require the presence of at least one bridging π-acceptor ligand capable of being involved in an initial metal to ligand charge transfer excitation. By “bridging ligand” we mean that, in the supramolecular complex, the π-acceptor ligand is located or positioned (i.e. bonded, coordinated) between an MLCT light absorber and an electron acceptor metal. Further, if there is more than one MLCT light absorber in the complex, the bridging π-acceptor ligands will be positioned to attach each light absorbing unit to either another light absorbing unit or directly to the electron accepting metal center.
The π-acceptor ligands coordinate or bind to the metal centers via donor atoms. Those of skill in the art will recognize that many suitable substances exist which contain appropriate donor atoms and may thus function as π-acceptor ligands in the complexes of the present invention. These π-acceptor ligands fall into two categories, bridging and terminal ligands. Bridging ligands serve to connect metal centers and thus bind to or coordinate two separate metal centers.
Terminal ligands bind or coordinate to only one metal center and serve to satisfy the needed coordination sphere for such metals and provide a means to tune both light absorbing and redox properties of that metal center. For example, substances with: nitrogen donor atoms (e.g. pyridine- and pyridimidine-containing moieties such as 2,2′-bipyridine (“bpy”); 2,2′:6′,2″-terpyridine (“tpy”); 2,3-bis(2-pyridyl)pyrazine (“dpp”); and 2,2′-bipyridimidine (“bpm”); 2,3-bis(2-pyridyl)quinoxaline; 2,3,5,6,-tetrakis(2-pyridyl)pyrazine; carbon and nitrogen donor atoms (e.g. 2,2′-phenylpyridine); phosphorus donor atoms (e.g. triphenylphosphine, diethylphenylphosphine); etc. In preferred embodiments of the present invention, the π-acceptor ligands are bpy, tpy, dpp and bpm.
Further, those of skill in the art will recognize that, depending on the number of available coordination sites on the metals to which the π-acceptor ligands are coordinated, other extraneous ligands may also be present to complete the coordination sphere of the metal. Examples of such ligands include but are not limited to halogens such as Cl and Br, COOH, CO, H2O, CH3CN, etc.
The electron acceptor metal is an essential component of this molecular design. Those of skill in the art will recognize that many metals may be used as the electron acceptor metal in the complexes of the present invention. Examples of suitable metals include but are not limited to rhodium(III), platinum(IV), cobalt(III), iridium(III). Any metal that can bind to a bridging π-acceptor ligand and accept an electron from the optically populated MLCT state to produce the reactive MMCT state may be utilized. In a preferred embodiment of the invention, the electron acceptor metal is rhodium(III). Further, the number of electron acceptor metal centers in the complex may also be varied. Multifunctional systems could be designed that use many electron acceptor sites to enhance the functioning of the system by providing additional bioactive sites within a single molecular architecture.
In general, the supramolecular architecture of the complexes of the present invention can be varied by changing the identity and number of components of the complex. However, it is necessary to retain the components in sufficiently close location and appropriate orientation to provide the necessary electronic coupling. This coupling is necessary to allow for electron transfer from the initial π-acceptor ligand, that accepts the charge in the initially populated metal to ligand charge transfer state, to the electron accepting metal center to lead to the formation of the reactive metal to metal charge transfer state. It is also important that component separation and orientation not allow for rapid relaxation of the reactive MMCT state, facilitated by rapid back electron transfer. Those of skill in the art will recognize that the precise distances between components and the orientation of the components will vary from complex to complex, depending on the identity of complex substituents. However, in general the distances will be confined to the multi-atomic or multi-angstrom scale.
Exemplary forms of the complexes of the invention contain two ruthenium- or osmiun-based light absorbers which are coupled to a biologically active rhodium metal site. In these embodiments, the light absorbing metal centers are occupied by Ru or Os, and the central electron acceptor metal site is occupied by Rh.
Preferred embodiments of the complexes include:
- [(bpy)2Ru(dpp)RhCl2(dpp)Ru(bpy)2](X)5
- [(bpy)2Os(dpp)RhCl2(dpp)Os(bpy)2](X)5
- [(tpy)RuCl(bpm)RhCl2(bpm)RuCl(tpy)](X)3 and
- [(tpy)RuCl(bpm)RhCl2(bpm)RuCl(tpy)](X)3;
where X is a counterion such as PF6 −, Cl−, Br−, CF3SO3 −, BF4 −, CLO4 −, SO4 2−, etc. Those of skill in the art will recognize that many such suitable counterions exist and may be utilized to form the salt form of a complex without altering the fundamental properties of the complex, other than its solubility.
The invention further provides new compositions of matter:
- [(bpy)2Os(dpp)RhCl2(dpp)Os(bpy)2](X)5
- [(tpy)RuCl(bpm)RhCl2(bpm)RuCl(tpy)](X)3 and
- [(tpy)RuCl(bpm)RhCl2(bpm)RuCl(tpy)](X)3;
where X is a counterion such as PF6 −, Cl−, Br−, CF3SO3 −, BF4 −, CLO4 −, SO4 2−, etc. as above.
The DNA cleaving agents of the present invention may be used for cleavage of DNA in many settings, including but not limited to cleavage of purified or partially purified DNA in laboratory setting for investigational purposes; and for the cleavage of DNA within cells, either ex vivo or in vivo. For example, ex vivo uses include cleavage of DNA in cultured cells for any reason, or of cells that have been removed from an individual with the intent of reintroducing the cells into the individual (or another individual) after manipulation of the cells (e.g. purging of tumor cells, genetic engineering of the cells, etc.) and the like. Examples of in vivo uses include the cleavage of DNA of cells within an organism, especially unwanted hyperproliferating cells such as tumor or cancer cells (including but are not limited to leukemia cells, ovarian cancer cells, Burkitt's lymphoma cells, breast cancer cells, gastric cancer cells, testicular cancer cells, and the like), and cells associated with psoriasis, warts, macular degeneration and other non-malignant hyperproliferating conditions.
While the method of the present invention is principally intended to thwart replication of hyperproliferating cells, other cellular populations may be targeted as well. For example, cells infected by a pathological agent such as a-virus or bacterium, may also be targeted.
Exposure of DNA to the agents of the present invention results in binding of the agents to the DNA and subsequent cleavage of the DNA. The cleavage pattern may be random. Alternatively, the complexes of the present invention may be purposefully designed to favor binding at particular regions of the DNA and so affect site specific (or at least site-preferential) cleavage. For example, the complexes may be designed to bind preferentially to a particular sequence of bases, or to a particular structural motif or location (e.g. to A-, B-, or Z-DNA, or to the major or minor groove). It is also possible to append to this supramolecular structure architecture recognition sites that would lead to site specific cleavage of DNA. For example, single stranded DNA sequences can be appended to the complexes to allow recognition of complementary strands and subsequent selective cleavage at the site of metal complex attachment. Further, proteins or fragments of proteins that bind selectively to specific regions of a DNA molecule may also be attached, e.g. topoisomerases, gyrases, DNA polymerases, etc. Methods of attaching or appending additional substituents to the complexes of the present invention would be well-known to those of skill in the art, e.g. by substitution of a non-essential ligand such as a terminal ligand. The complexes may be used to cleave either double- or single-stranded DNA, as well as DNA-RNA hybrids, and double- or single-stranded RNA.
In preferred embodiments, the agents of the present invention bind to and cleave DNA within cells for which it is desired to attenuate the ability to replicate. Without being bound by theory, the agents of the present invention appear to provide a less drastic mode of treating pathological conditions which result from the hyperproliferation of cells in that the agents appear to cause a cessation of replication without killing the hyperproliferating cells outright. This is an advantage because the immediate killing of, for example, all tumor cells in a tumor mass can have unwanted results for a patient in which the tumor is being treated. If millions of tumor cells are killed outright many or most of the cells undergo lysis, releasing their contents into the environment. The result of such a massive release of the contents of dead cells into an area of the body can generate, for example, inflammatory and other unwanted reactions in otherwise healthy tissue in the environment. By biasing the effects of the agent to a cessation of replication, the progression of the tumor is halted, and the tumor cells will relatively gradually undergo cell death. Thus, the body of the patient under treatment experiences less drastic treatment consequences. However, those of skill in the art will recognize that some cells in the hyperproliferating tissue may also be killed outright by exposure to the DNA cleaving agents of the present invention. Other potential benefits could include attenuation of the cancer cells that would make them more susceptible to other types of cell killing such as chemotherapy or radiotherapy. Indeed, the methods of the instant invention may be practiced in conjunction with other such therapeutic measures.
The present invention provides specificity in attenuating cellular proliferation in that activation of DNA cleavage and subsequent cell damage and/or death will occur only when the cells containing the cleavage agent are exposed to suitable wavelengths of light. Suitable wavelengths of light for use in the practice of the present invention are dependent on the components of a given supramolecular complex. In general, low energy, visible light is utilized. By “low energy, visible light” we mean light of wavelengths >475 nm. For example, the wavelength used will depend on the complex of interest and its ability to absorb at that wavelength as well as the ability of the wavelength of light to penetrate the applicable biological material. Typically excitation would occur in the region of the intense metal to ligand charge transfer excitation. For example, for the system [{(bpy)2Ru(dpp)}2RhCl2](PF6)5 the lowest lying such MLCT transition center is at 514 nm so optimal excitation would occur in this region (±about 50 nm) i.e. from about 464 to about 564 nm. However, those of skill in the art will recognize that other excitations further from the optimum can also be used due to the efficient internal conversion within supramolecular complexes of the type described herein. For example, for the system [{(bpy)2Ru(dpp)}2RhCl2](PF6)5 excitation is possible throughout the UV and into the visible region, i.e. from about 200 to 650 nm. Light for in vivo applications where significant penetration is needed would typically be in the therapeutic window of about 650 to about 950 nm.
Specificity also results in that, when the targeted cells are in vivo (i.e. located internally within an organism), they will be exposed to light only when light of an appropriate wavelength is deliberately introduced into the environment, for example, during a studied surgical procedure using, e.g., optical fibers. For endoscopic use, optical fibers are threaded through a catheter or endoscope, allowing for small incisions while delivering a focused beam of light. When the targeted cells are ex vivo, cells are shielded until light of the wavelength that would activate the photosensitizing agent could be purposefully administered. Many companies (such as Coherent Medical Group, Coherent Inc., Palo Alto, Calif.), manufacture products specifically designed for the production of narrow wavelengths of light required for medical use. Those of skill in the art are acquainted with and will recognize that many such products exist. For example, gas lasers as well as LEDs are commercially available and capable of producing the requisite light. Any appropriate means of illuminating the target cells that results in activation of the photosensitizer molecule within the target cells, so that injury or death of the target cells results, may be utilized in the practice of the present invention. For example, of such methods of illumination, see Bellnier, D. et al. 1999. Design and construction of a light-delivery system for photodynamic therapy. Med. Phys. 26: 1552.
Specificity may also be conferred by the attachment to the complex of moieties which serve to direct the complex to a desired target. The agents may be coupled to targeting moieties such as antibodies, lectins, targeting fragments such as bacterial toxin molecules or fragments of such molecules, all of which can serve to direct the cleaving agent to the targeted population of cells, and also to promote uptake of the complex by the cell. For example, by coupling a DNA cleaving agent of the present invention to an antibody specific for an antigen that is expressed on a particular type of tumor cell, the agent can be delivered to the tumor cells of interest. See, for example, U.S. Pat. No. 6,426,400 to Zalutsky (Jul. 30, 2002) and U.S. Pat. No. 6,492,123 to Hollinger et al., (Dec. 10, 2002), the complete contents of which are hereby incorporated by reference.
Delivery of the DNA cleaving agents of the present invention to the DNA to be cleaved may be carried out by any of several known methods and will vary from case to case, depending on the particular application. For example, for some laboratory applications, solutions of the agents may be mixed directly with the DNA to be cleaved. For the cleavage of cultured cells (including ex vivo cells) the cleaving agents of the present invention may be added directly to the culture media where they are taken up by the cells. For in vivo applications, those of skill in the art will recognize that many means of administration exist, including but not limited to: direct application of the DNA cleaving agent in a suitable carrier, e.g. by topical administration to a cancerous lesion such as a melanoma or other area of exposed hyperproliferating tissue; or by delivery directly into the tumor or other hyperproliferating tissue, e.g. by injection or other type of direct infusion. Other means of delivery include systemic delivery. In the case of systemic delivery, many cells will be exposed to and internalize the agents of the present invention. However, only those cells which are later exposed to suitable wavelengths of light will be effected by the presence of the agent by cleavage of their DNA. Residual agent within non-targeted cells will be eliminated from the body over a time period of about two weeks, during which the patient must avoid exposure to wavelengths of light that would activate the agents.
Thus, the agents of the present invention may be administered by any of several suitable means that are well-known to those of skill in the art. For example, intramuscularly, intravenously, intratumorally, orally (e.g. in liquid or tablet/capusular form), via suppositories, via inhalation, and the like.
In order to effect administration of the agents of the present invention, the present invention also provides a composition for administration to hyperproliferating cells. The composition comprises at least one of the DNA cleaving agents and a suitable carrier, e.g. a suitable physiological carrier for in vivo administration, e.g. saline. The composition may be administered in any of a variety of suitable forms, including forms that include additional components such as buffers, stabilizers, nutrients, anti-oxidants, flavorings, colorants, and the like, which are appropriate to a means of administration. Those of skill in the art will recognize that the exact form will vary from application to application. The compounds can be administered in the pure form or in a pharmaceutically acceptable formulation including suitable elixirs, binders, and the like or as pharmaceutically acceptable salts or other derivatives. It should be understood that the pharmaceutically acceptable formulations and salts include liquid and solid materials conventionally utilized to prepare injectable dosage forms and solid dosage forms such as tablets and capsules. Water may be used for the preparation of injectable compositions which may also include conventional buffers and agents to render the injectable composition isotonic. Solid diluents and excipients include lactose, starch, conventional disintegrating agents, coatings and the like. Preservatives such as methyl paraben or benzalkium chloride may also be used. Depending on the formulation, it is expected that the active composition will consist of 1-99% of the composition and the vehicular “carrier” will constitute 1-99% of the composition.
Likewise, the dosage, frequency and liming of administration will vary from case to case and will depend on factors such as the particular application, the nature and stage of a condition resulting from hyperproliferation of cells (e.g. size and location of a malignant or non-malignant tumor), characteristics of the patient (e.g. overall health, age, weight, gender and the like), and other factors such as ancillary treatments (chemotherapy, radiotherapy, and the like). The details of administration are best determined by a skilled practitioner such as a physician. Further, the details of administration are normally worked out during clinical trials. However, the approximate dosage range will preferably be from about 0.1 to 10 mg of agent per kg of weight, and more preferably from about 0.25 to 1.0 mg/kg. When treating DNA directly, the amount of agent to be administered is preferably in the range of about 0.1-50 μg per about 0.1-50 μg of DNA, and more preferably, in the range of about 1-10 μg per about 1-10 μg of DNA. Those of skill in the art will recognize that the precise amounts will vary depending, for example, on the precise characteristics of the complex and the DNA itself, on temperature, pH, and the like. Typically, the agent will be administered about 1 to 24 hours prior to exposure to a suitable light source, and preferably from about 1 to 4 hours prior to exposure to the light source.
Likewise, the dose or frequency of illumination of the target cells will vary from case to case, but will generally be in the range of 25-200 J/cm2 light dose, 25-200 mW/cm2 fluence rate (see Ochsner, M. 1997. Photodynamic Therapy: the Clinical Perspective. Review on applications for control of diverse tumours and non-tumour diseases. Drug Res., 47:1185-1194).
Further non-limiting embodiments of the invention are presented in the following Examples section.
Interest in the area of supramolecular chemistry has resulted in the design of many photochemically and electrochemically active ruthenium(II) polypyridyl complexes.1-17 Supramolecular complexes have been designed, taking advantage of the long-lived metal-to-ligand charge transfer (MLCT) excited state of the widely studied [Ru(bpy)3]2+ chromophore,1-3 focused on their use as photochemical molecular devices4-9 (bpy) 2,2′-bipyridine. Incorporation of ruthenium(II) polypyridyl groups into a supramolecular motif eliminates the need for molecular collision resulting in facile electron or energy transfer. The bridge, which links the metal centers in these supramolecular complexes, is often a multidentate polyazine ligand.4-17
Polymetallic complexes incorporating polyazine bridging ligands (BL) have received a great deal of attention.4-17 The BL serves to bring the metal centers into close proximity and creates a pathway for energy or electron transfer. The commonly used bridging ligand 2,3-bis(2-pyridyl)pyrazine (dpp) (FIG. 1A ) binds to two metal centers through a pyridyl and a pyrazine nitrogen, acting as an AB chelate, resulting in a mixture of stereoisomers not typically separated.4-9,12,14,15 Another BL which performs the same function but has not received as much attention is 2,2′-bipyrimidine (bpm) (FIG. 1B ), which binds to two metal centers through two equivalent nitrogens eliminating the stereoisomers associated with the AB chelates.11,13,16,17
Within a supramolecular architecture, terminal ligands (TL), typically bpy, are coordinated to the ruthenium light absorbers. Another TL used in supramolecular complexes is 2,2′:6′,2″-terpyridine (tpy) (FIG. 1C ). Although [Ru(tpy)2]2+ has a short-lived excited state,18-20 the tpy ligand brings the advantage of eliminating the Δ and Λ isomeric mixtures associated with the tris-bidentate metal centers giving some stereochemical control in supramolecular complexes. Long lived excited states are observed for many ruthenium tpy complexes incorporating polyazine bridging ligands.21-30
Trimetallic complexes of the form [{(bpy)2Ru(BL)}2MCl2]5+, where BL=dpp, 2,3-bis(2-pyridyl)quinoxaline (dpq), and 2,3-bis(2-pyridyl)benzoquinoxaline (dpb) and M=Ir(III),31-33 have been studied, and a preliminary report of M=Rh(III) has appeared.32b The system with M=Ir and BL=dpb acts as a molecular device for photoinitiated electron collection31a and is an electrocatalyst for CO2 reduction.33 The bpm trimetallic complexes [{(bpy)2Ru(bpm)}2IrCl2]5+ and [{(bpy)2Ru(bpm)}2RhCl2]5+ have Ru-(dπ) based highest occupied molecular orbitals (HOMOs) and bridging ligand, bpm(π*), based lowest unoccupied molecular orbitals (LUMOs).34
A number of important studies on the coupling of ruthenium light absorbers to rhodium electron acceptors in suprammolecular frameworks have appeared.32,34-44 Interesting systems with varying bridge length were studied by Indelli, Scandola, Collin, Sauvage, and Sour, [(tpy)Ru(tpy(Ph)ntpy) Rh(tpy)]5+ (n=0, 1, or 2).36 Linked bpy systems of the type [(Me2phen)2RuII(Mebpy-CH2CH2-Mebpy)RhIII(Mebpy)2]5+ 36,37 and a dpp bridged system [(bpy)2RuII(dpp)RhIII(bpy)2]5+ 35 have been investigated. Endicott et al. have studied RuII, RhIII cyanide-bridged complexes.41 Often these systems are reported to undergo intramolecular electrontransfer quenching of the Ru-based MLCT excited state by the rhodium center.
A trimetallic structural motif would be an interesting framework to exploit the electron acceptor properties of the rhodium metal center. This requires the development of synthetic methods and the ability to modulate orbital energies in a supramolecular architecture. Within this framework the trimetallic complexes [{(tpy)RuCl(dpp)}2RhCl2](PF6)3 and [{(tpy)RuCl(bpm)}2RhCl2](PF6)3 have been synthesized and characterized by FAB mass spectral analysis, electronic absorption spectroscopy, electrochemistry, and spectroelectrochemistry. These complexes couple two ruthenium light absorbers (LA) to a central electron collecting (EC) rhodium metal center to form a LA-BL-EC-BL-LA assembly. The interesting effects of bridging ligand and terminal ligands on the spectroscopic and electrochemical properties of these complexes is discussed.
Materials.
2,2′:6′,6″-Terpyridine (tpy) (GFS chemicals), ruthenium(III) chloride hydrate, rhodium trichloride hydrate, and 2,2′-bipyrimidine (bpm) (Alfa), triethylamine (Acros), 2,3-bis(2-pyridyl)-pyrazine (dpp) (Aldrich), (80-200 mesh) adsorption alumina (Fisher), and spectroquality grade acetonitrile and toluene (Burdick and Jackson) were used as received. Tetrabutylammonium hexafluorophosphate Bu4NPF6 (used as supporting electrolyte for electrochemistry experiments) was prepared by the aqueous metathesis of tetrabutylammonium bromide (Aldrich) with potassium hexafluorophosphate (Aldrich). After several recrystallizations from ethanol the white crystals were dried under vacuum and stored in a vacuum desiccator. Elemental analysis was performed by Galbraith Laboratories, Inc., Knoxville, Tenn.
Synthesis.
(tpy)RuCl3,45 [(tpy)RuCl(dpp)](PF6),46 [(tpy)RuCl(bpm)](PF6),47 [{(bpy)2Ru(dpp)}2RhCl2](PF6)5,32b and [{(bpy)2Ru(bpm)}2RhCl2](PF6)5 34 were synthesized as described previously.
[{(tpy)RuCl(dpp)}2RhCl2](PF6)3.
A solution of 0.40 g (0.54 mmol) of [(tpy)RuCl(dpp)](PF6) and 0.080 g (0.36 mmol) of rhodium trichloride hydrate in 2:1 EtOH/H2O was heated at reflux for 1 h. After being cooled to room temperature, the reaction mixture was added dropwise to an aqueous solution of 100 mL of H 20 and 100 mL of saturated KPF6(aq) solution with stirring. The resulting precipitate was filtered, washed with 30 mL of cold water and 30 mL of cold ethanol followed by 30 mL of ether, and air-dried for 30 min. The product was dissolved in a minimum amount of acetonitrile (ca. 5 mL), flash precipitated in 200 mL of ether, and collected by vacuum filtration to yield a purple powder (0.40 g, 0.22 mmol, 82% yield). Anal. Calcd for [{(tpy)RuCl(dpp)}2RhCl2](PF6)3, 8H2O; C, 35.52; H, 2.98; N, 10.00. Found: C, 35.20; H, 2.35; N, 9.93. UV/vis (CH3CN): λmax (nm) [ex 10−4 M−1 cm−1]) 274 [4.70], 314 [6.48], 360 (sh) [2.72], 460 [1.13], 540 [2.72]. FAB-MS ion (m/z; relative abundance): [{(tpy)RuCl(dpp)}2RhCl2](PF6)2 + (1673, 100); [{(tpy)RuCl(dpp)}2RhCl](PF6)2 + (1636, 10); [{(tpy)RuCl(dpp)}2RhCl2](PF6)+ (1527, 25); [{(tpy)RuCl(dpp)}2RhCl](PF6)+ (1493, 10).
[{(tpy)RuCl(bpm)}2RhCl2](PF6)3.
A solution of 0.32 g (0.49 mmol) of [(tpy)RuCl(bpm)](PF6) and 0.070 g (0.32 mmol) of rhodium trichloride hydrate in 2:1 EtOH/H2O was heated at reflux for 2 h. After the reaction mixture was cooled to room temperature, a black residue was removed by filtration. The filtrate was added dropwise to an aqueous solution of 100 mL of H 20 and 1002 mL of saturated KPF6(aq) solution with stirring. A brown precipitate formed, which was filtered and washed with 30 mL of cold ethanol followed by 30 mL of ether. The resulting brown product was dissolved in a minimum of acetonitrile (ca. 5 mL), flash precipitated in 200 mL of ether, and collected by vacuum filtration to yield a greenish/brown powder (0.28 g, 0.17 mmol, 72% yield). Anal. Calcd for [{(tpy)RuCl(bpm)}2RhCl2](PF6)3, CH3CN, H2O; C, 33.45; H, 2.28; N, 12.19. Found: C, 33.33; H, 2.40; N, 11.76. UV/vis (CH3CN): λmax (nm) [ε×10−4 M−1 cm−1]) 272 [6.21], 312 [5.50], 330 (sh) [3.11], 464 [2.50], 656 [1.00]. FAB-MS ion (m/z; relative abundance): [{(tpy)RuCl(bpm)}2RhCl2](PF6)2+(1520, 85); [{(tpy)RuCl(bpm)}2RhCl](PF6)2 + (1485, 15); [{(tpy)RuCl(bpm)}2RhCl2](PF6)+ (1375, 100); [{(tpy)RuCl(dpp)}2RhCl](PF6)+ (1340, 20).
Electronic Spectroscopy.
Electronic absorption spectra were recorded at room temperature using a Hewlett-Packard 8452 diode array spectrophotometer with 2 nm resolution. Samples were run at room temperature in Burdick and Jackson UV-grade acetonitrile in 1 cm quartz cuvettes.
Electrochemistry.
Cyclic voltammograms were recorded using a one-compartment three-electrode cell, Bioanalytical Systems (BAS), equipped with a platinum wire auxiliary electrode. The working electrode was a 1.9 mm diameter glassy carbon disk from BAS. Potentials were referenced to a Ag/AgCl electrode (0.29 V vs NHE), which was calibrated against the FeCp2/FeCp2 + redox couple (0.67 V vs NHE).48 The supporting electrolyte was 0.1 M Bu4NPF6, and the measurements were made in Burdick and Jackson UV-grade acetonitrile, which was dried over 3 Å molecular sieves.
Spectroelectrochemistry.
Spectroelectrochemical measurements were conducted according to a previously described method using a locally constructed H-cell which uses a quartz cuvette as the working compartment.49 The working and auxiliary compartments were separated by a fine porous glass frit. The working electrode and auxiliary electrodes were high surface area platinum mesh, and the reference electrode was Ag/AgCl (0.29 V vs NHE). The measurements were made in 0.1 M Bu4NPF6/acetonitrile solutions that were 2×10−5 M metal complex. The electrolysis potential was controlled by a BAS 100 W electrochemical analyzer.
FAB Mass Spectrometry.
FAB mass spectral analysis was performed by M-Scan Incorporated, West Chester, Pa., on a VG Analytical ZAB 2-SE high-field mass spectrometer using m-nitrobenzyl alcohol as a matrix. The trimetallic gave very nice FABMS patterns with sequential loss of each PF6 ion being observed. The fragmentation pattern was consistent with the proposed molecular structure.
The supramolecular complexes [{(tpy)RuCl(dpp)}2RhCl2](PF6)3 and [{(tpy)RuCl(bpm)}2RhCl2](PF6)3 were prepared in good yields under mild conditions using a building-block approach. It is this method that allows for easy variation of structural components within this structural motif. The tpy is first bound to ruthenium followed by BL attachment.45,46 The trimetallic complexes are assembled by reaction of the [(tpy)RuCl(BL)](PF6), where BL=dpp or bpm, with a slight excess of rhodium(III) trichloride hydrate. The synthesis of [{(tpy)RuCl(bpm)}2RhCl2](PF6)3 by this method is illustrated in FIG. 2 . This method of binding the bpm or dpp ligand to the ruthenium metal center first and then binding to the rhodium metal center yields clean reactions with easily purified products. The use of excess rhodium(III) trichloride hydrate ensures that most of the monometallic precursor is reacted. The major product in each case is the desired trimetallic. The excess rhodium(III) trichloride is easily removed by aqueous washings of the precipitated hexafluorophosphate salt of the trimetallic complex.
The use of dpp as a bridging ligand leads to cis and trans type stereoisomers, around the Ru which are not detectable by cyclic voltammetry or electronic absorption spectroscopy.46,47 Utilization of the symmetric bridging ligand bpm eliminates the cis/trans type stereoisomers present in the dpp synthons.
These trimetallic complexes were effectively characterized by FAB mass spectral analysis. These supramolecular complexes typically show high mass peaks that are easy to interpret with loss of counterions and intact ligands. Fragmentation patterns for these trimetallics show sequential loss of PF6 − counterions and the chlorides bound to the rhodium center.
This example demonstrates that a method has been developed to prepare such complexes that is general and allows for component modification and that the described complexes have the proposed formulation.
Trimetallic complexes of the form [{(bpy)2Ru(CL)}2RhCl2]5+ are characterized by reversible ruthenium oxidations, irreversible rhodium reductions, and reversible ligand reductions, with the BLs (dpp or bpm) being reduced prior to the bpy ligands.32,34 They display a Ru(dσ) HOMO. The LUMO is localized on Rh(dσ*) for dpp and bpm(π*) for the bpm bridged system.
The cyclic voltammogram of [{(tpy)RuCl(dpp)}2RhCl2]3+ in 0.4 M Bu4NPF6/CH3CN solution is illustrated in FIG. 4A and summarized in Table 1.
| TABLE 1 |
| Electrochemical Properties for a Series of Ru(II) and Ru(II)/Rh(III)/ |
| Ru(II) Trimetallic Complexes Where tpy = 2,2′:6′,2″- |
| Terpyridine, dpp = 2,Bis(2-pyridyl)pyrazine, |
| and bpm = 2,2′-Bipyrimidine |
| E1/2 in Va (ΔEp in mV) | assignment |
| [{(tpy)RuCl(dpp)}2RhCl2](PF6)3 |
| 1.12 (85) | 2RuIII/II |
| Ep c = 0.47 | RhIII/I |
| −0.87 (140) | dpp, dpp/dpp, dpp− |
| −1.20 (95) | dpp, dpp−/dpp−, dpp− |
| [{(tpy)RuCl(bpm)}2RhCl2](PF6)3 |
| 1.12 (100) | 2RuIII/II |
| Ep c = −0.26 | RhIII/I |
| Ep c = −0.38 | RhII/I |
| −0.70 (100) | bpm, bpm/bpm, bpm− |
| −1.12 (115) | bpm, bpm−/bpm−, bpm− |
| [{(bpy)2Ru(dpp)}2RhCl2](PF6)5-32b |
| 1.6 | 2RuIII/II |
| Ep c = −0.39 | RhIII/I |
| −0.79 | dpp, dpp/dpp, dpp− |
| −1.02 | dpp, dpp−/dpp−, dpp− |
| [{(bpy)2Ru(bpm)}2RhCl2](PF6)5 34 |
| 1.7 | 2RuIII/II |
| −0.13 | bpm, bpm/bpm, bpm− |
| −0.26 | bpm, bpm−/bpm−, bpm− |
| −0.78 | RhIII/I |
| [(tpy)RuCl(dpp)](PF6)47 |
| 1 | RuIII/II |
| −1.21 | dpp0/— |
| −1.54 | tpy0/— |
| [(tpy)RuCl(bpm)](PF6)47 |
| 1.01 | RuIII/II |
| −1.15 | bpm0/— |
| −1.56 | typ0/— |
| aPotentials reported versus the Ag/AgCl (0.29 V vs NHE) reference electrode in 0.1 M Bu4NPF6CH3CN. | |
A reversible redox couple at 1.12 V is observed in the positive potential region. This redox couple is attributed to two overlapping RuII/III oxidations. These LAs are largely electronically uncoupled, allowing them to function independently.31,34 The RuII/III couples occur 480 mV less positive in the [{(tpy)RuCl(dpp)}2RhCl2]3+ systems relative to the bpy systems, resulting from the chloride coordination on the Ru centers in the tpy systems. Reductively an irreversible peak is observed at −0.47 V. This couple results from the overlapping reduction of the Rh(III) to Rh(II) and then to Rh(1). Similar behavior is reported by DeArmond for the [Rh(bpy)2Cl2]+.50 Reduction of the Rh(III) to Rh(I) should be followed by conversion of the formally d6 pseudocathedral Rh(III) to a square planar d8 Rh(I). This occurs by chloride loss as evidenced by the presence of free chloride seen in anodic scans that follow cathodic scans through the RhIII/I couple. No evidence of Rh(I) reoxidation is seen in multiple scan experiments. Two quasi-reversible redox couples at −0.87 and −1.20 V are attributed to sequential reduction of the two equivalent dpp bridging ligands, dpp,dpp/dpp,dpp− and dpp,dpp−/dpp−,dpp−, respectively. Further reductive scanning results in a neutral species leading to adsorption of the complex onto the electrode surface. [{(tpy)RuCl(dpp)}2RhCl2]3+ exhibits a ruthenium(I) based HOMO and a rhodium(III) based LUMO, analogous to [{(bpy)2Ru(dpp)}2RhCl2]5+. The proposed electrochemical mechanism is shown in FIG. 5 . The cyclic voltammogram of [{(tpy)RuCl(bpm)}2RhCl2]3+ in 0.4 M Bu4NPF6/CH3CN solution is illustrated in FIG. 4B and summarized in Table 1. A single reversible oxidation wave is observed at E1/2=1.21 V and is assigned to the two overlapping RuII/III redox couples, indicating that the two ruthenium centers are largely electronically uncoupled. Two closely spaced irreversible reductions at −0.26 and −0.38 V in FIG. 4B are assigned as sequential one-electron reductions of the rhodium center, RhIII/II and RhII/I. Interestingly, when bpm is used as the BL these two couples shift apart relative to the dpp analogue, indicating some stability of the Rh(II) oxidation state. This is an unusual property for a [Rh(NN)2Cl2]′ system. Reversing the scan after the RhIII/II couple but prior to the Rh II/I couple does lead to the observation of a small return wave corresponding to Rh(II) reoxidation, but this couple remains largely irreversible. Further cathodic scanning past the RhII/I couple reveals the sequential one-electron reduction of the bpm bridging ligands, bpm,bpm/bpm,bpm− and bpm,bpm−/bpm−,bpm−. Further reduction leads to adsorption.
The new bpm-based trimetallic complex [{(tpy)RuCl(bpm)}2RhCl2]3+ displays a Rh(dσ*) LUMO in marked contrast to the bpm(π*) LUMO in [{(bpy)2Ru(bpm)}2RhCl2]5+. The redox chemistry of [{(bpy)2Ru(bpm)}2RhCl2]5+ is characterized by two reversible one-electron bpm− based reductions at −0.13 and −0.26 V followed by the irreversible reduction of the rhodium center, RhIII/I, at −0.78 V.34 Variation of the terminal ligands on the Ru metals indirectly modulates the energy of the bpm ligand orbitals. Coordination of the Cl− ligand to ruthenium in [{(tpy)RuCl(bpm)}2RhCl2]3+ results in a more electron rich Ru center. This leads to less stabilization of the bpm(π*) orbitals relative to the bis-bpy analogue. As the bpm(π*) and Rh(dσ*) orbitals are very close in energy, this modulation of the bpm(π*) orbital energies by terminal ligand variation leads to orbital inversion, FIGS. 3A and 3B .
This electrochemical data indicates that, in the trimetallic complexes [{(tpy)RuCl(BL)}2RhCl2]3+ and [{(bpy)2Ru(BL)2RhCl2]5+, the BL(M) and Rh(dσ*) orbitals are close in energy. In all cases the HOMO is localized on the Ru(dπ) orbitals. The localization of the LUMO can be modulated, being Rh(dσ*) in nature for [{(tpy)RuCl(BL)}2RhCl2]3+ (BL=dpp or bpm) and [{(bpy)2Ru(dpp)}2RhCl2]5+ and bpm(π*) in nature for [{(bpy)2Ru(bpm)}2RhCl2]5+.
This example demonstrates that the complexes display redox patterns consistent with their formulation. Additionally, the systems possess the necessary energetics to undergo the needed metal to ligand charge transfer excitation followed by intramolecular electron transfer to produce the desired reactive metal to metal charge transfer state.
The electronic absorption spectral data in acetonitrile of the new trimetallic complexes, [{(tpy)RuCl(dpp)}2RhCl2]3+ and [{(tpy)RuCl(bpm)}2RhCl2]3+, as well as their monometallic precursors and trimetallic bpy analogues are assembled in Table 2. The UV regions of the spectra for all of these complexes show BL (dpp or bpm) and terminal ligand (tpy or bpy) π to π* transitions with the BLs expected to show the lowest lying π to π* bands.1,4-9,34,47,51 The visible regions of the spectra are dominated by overlapping Ru(d π) to BL(π*) and Ru(d π) to bpy or tpy(π*) charge transfer (CT) transitions with BL based bands occurring at lower energy.
| TABLE 2 |
| Electronic Absorption Spectroscopy for a Series of Ru(II) and |
| Ru(II)/Rh(III)/Ru(II) Trimetallic Complexes Where |
| tpy = 2,2′:6′,2″-Terpyridine, |
| dpp = 2,3-Bis(2-pyridyl)pyrazine, and bpm = 2,2′-Bipyrimidinea |
| λmax (nm) | ε × 10−4 (M−1 cm−1) | assignments | ||
| [{(tpy)RuCl(dpp)}2RhCl2](PF6)3 |
| 274 | 4.7 | tpy(π→ π*) | |
| 314 | 6.48 | tpy(π→π*) | |
| 330(sh) | 5.41 | Ru(dπ)→ tpy(π*) CT | |
| 360(sh) | 2.72 | dpp(π→ π*) | |
| 460 | 1.13 | Ru(dπ)→ tpy(π*) CT | |
| 540 | 2.72 | Ru(dπ)→ dpp(π*) CT |
| [{(tpy)RuCl(bpm)}2RhCl2](PF6)3 |
| 272 | 6.21 | tpy(π→ π*) | |
| 312 | 5.5 | tpy(π→ π*) | |
| 330(sh) | 3.11 | Ru(dπ)→ tpy(π*) CT | |
| bpm (π→ π*) | |||
| 464 | 2.5 | Ru(dπ)→ tpy(π*) CT | |
| Ru(dπ)→ bpm(π*) CT | |||
| 656 | 1 | Ru(dπ)→ tpy(π*) CT |
| [{(bpy)2Ru(dpp)}2RhCl2](PF6)5 b |
| 242 | 6.53 | bpy(π→ π*) | |
| 284 | 9.64 | bpy(π→ π*) | |
| 344(sh) | 2.87 | dpp (π→ π*) | |
| 414 | 1.74 | Ru(dπ)→ bpy(π*) CT | |
| 514 | 2.01 | Ru(dπ)→ dpp(π*) CT |
| [{(bpy)2Ru(bpm)}2RhCl2](PF6)5 34 |
| 278 | 9 | bpy(π→ π*) | |
| 412 | 3.7 | Ru(dπ)→ bpy(π*) CT | |
| Ru(dπ)→ bpm(π*) CT | |||
| 594 | 0.99 | Ru(dπ)→ bpm(π*) CT |
| [(tpy)RuCl(dpp)](PF6)47 |
| 238 | 2.32 | dpp(π→ π*) | |
| 276 | 2 | tpy(π→ π*) | |
| 314 | 2.91 | tpy(π→ π*) | |
| 370 | 0.44 | Ru(dπ)→ tpy(π*) CT | |
| 514 | 0.89 | Ru(dπ)→ tpy(π*) CT |
| [(tpy)RuCl(bpm)](PF6)47 |
| 240 | 3.94 | bpm (π→ π*) | ||
| 266 | 2.92 | tpy (π→ π*) | ||
| 316 | 3.31 | tpy (π→ π*) | ||
| 370 | 0.96 | Ru(dπ)→ tpy(π*) CT | ||
| 516 | 0.99 | Ru(dπ)→ tpy(π*) CT | ||
| Ru(dπ)→ bpm(π*) CT | ||||
| aAbsorption spectra taken in acetonitrile at room temperature. | ||||
| bLowest energy CT transitions taken from ref 32b. | ||||
The electronic absorption spectra for [{(tpy)RuCl(dpp)}2RhCl2]3 and [{(tpy)RuCl(bpm)}2RhCl2]3+ in acetonitrile are characterized by high-energy tpy and BL (π to π*) transitions, with tpy bands at 274 nm and 314 nm. A shoulder observed at ca. 340 or 360 nm is attributed to the BL (π to π*) transition for dpp and bpm, respectively.31b Significant spectral differences between these two trimetallics becomes apparent when the visible regions of the spectra are compared. The lowest energy transition at 540 nm for [{(tpy)RuCl(dpp)}2RhCl2]3+, which contains the Ru(dπ) to dpp(π*) CT transition, is 116 nm higher in energy than the corresponding transition for the bpm analogue. This suggests that the impact of the rhodium coordination on the BL π* orbitals is more dramatic for bpm than dpp, consistent with the electrochemical behavior.47
A comparison of the electronic absorption spectra of the trimetallic, [{(tpy)RuCl(dpp)}2RhCl2]3+, and its monometallic precursor, [(tpy)RuCl(dpp)]+, reveals some interesting features. The UV regions of the spectra are virtually identical, consisting of dpp and tpy based π to π* transitions. As expected, these transitions are more intense for the trimetallic complex, in keeping with its molecular structure. Coordination of two monometallic precursors, [(tpy)RuCl(dpp)]+, to the rhodium metal center red shifts the Ru(dπ) to dpp(π*) CT transition from 516 nm for the monometallic to 540 nm. This results from rhodium coordination stabilizing the dpp-(π*) orbitals of the trimetallic, consistent with the electrochemical behavior of the title trimetallic. The Ru(dπ) to dpp(π*) CT band at 540 nm in [{(tpy)RuCl(dpp)}2RhCl2]3+ is red shifted relative to 514 nm in [{(bpy)2Ru(dpp)}2RhCl2]5+. This shift is due to higher energy Ru(dπ) orbitals in [{(tpy)RuCl(dpp)}2RhCl2]3+ due to the coordinated chloride, also consistent with the electrochemical data.
The UV regions of the spectra for the bpm monometallic, [(tpy)RuCl(bpm)]+, and the trimetallic, [{(tpy)RuCl(bpm)}2RhCl2]3+, complexes are very similar, with intense intraligand π to π* transitions from bpm and tpy. Upon coordination of the monometallic to the rhodium metal center, the Ru(dπ) to bpm(π*) CT transition at 516 nm red shifts to 656 nm. This is the result of stabilization of the bpm(π*) orbitals from coordination of the electron-withdrawing rhodium center. This 656 nm Ru(d π) to bpm(π*) CT transition of the title trimetallic is red shifted relative to the 594 nm peak in the bpy analogue [{(bpy)2Ru(bpm)}2RhCl2]5+, consistent with the electrochemical data.
Both title trimetallics [{(tpy)RuCl(BL)}2RhCl2]3+ possess Ru(dπ) based HOMOs and Rh(dσ*) LUMOs. Spectroscopically, no optical transition is seen representing this metalto-metal charge transfer (MMCT) excitation. This likely results from the high extinction coefficient for the lowest energy Ru(dπ) to BL(π*) CT transition and the low overlap of the Ru(d π) and Rh(dσ*) orbitals leading to low intensity of the MMCT transition. Energetically, this MMCT state lies lower in energy than the optically populated MLCT state. This should lead to the intramolecular electron transfer to the Rh center in these complexes leading to quenching of the MLCT emission, discussed below.
This example demonstrates that these complexes are efficient light absorbers and that they undergo excitation into a metal to ligand charge transfer state with a high extinction coefficient. Additionally, this example demonstrates that the energy of this excitation can be tuned by simple component modification within this supramolecular architecture.
Spectroelectrochemistry was used to study the electronic absorption spectroscopy and cyclic voltammetry of the title trimetallics. The spectroelectrochemistry of [{(tpy)RuCl(dpp)}2RhCl2]3+ and [{(tpy)RuCl(bpm)}2RhCl2]3+ is shown in FIGS. 6A and 6B . The two-electron oxidation of [{(tpy)RuCl(dpp)}2RhCl2]3+ is greater than 95% reversible. Electrolysis at 1.35 V, past the RuIII/II a redox couple, shows a loss of the absorption band at 540 nm. This is consistent with its assignment as a Ru(dπ) to dpp(π*) CT transition. The absorption band at 314 nm and its lowest energy shoulder at 360 nm broaden and shift to lower energy upon oxidation of the ruthenium metal centers, consistent with a ligand-based (π to π*) transition.31 A component (at ca. 330 nm) is lost upon oxidation of the ruthenium centers, consistent with a higher energy Ru(dπ) to tpy(π*) CT transition occurring in this region. Similar behavior has been reported for the oxidation of an array of Ru(tpy) moieties.52,53 Reduction of the trimetallic complex was irreversible due to reaction of the reduced rhodium center, consistent with the Rh(dσ*) nature of the LUMO.
Very similar spectroelectrochemistry is observed for the bpm-bridged trimetallic, [{(tpy)RuCl(bpm)}2RhCl2]3+, FIG. 6B . Oxidation of the ruthenium centers at 1.45 V is greater than 95% reversible. This electrolysis leads to the loss of the absorption bands at ca. 330, 464, and 656 nm, consistent with their assignment as higher energy Ru(dπ) to tpy(π*), Ru(dπ) to tpy(π*), and Ru(dπ) to bpm(π*) CT transitions, respectively. A broadening and red shift of the absorption band at 312 nm and shoulder at ca. 340 nm is consistent with overlapping intraligand π to π* transitions. Reduction was irreversible, consistent with a Rh(dσ*) LUMO.
We were unable to detect any emission from the title trimetallics at room temperature or 77 K in acetonitrile solutions. This may result from the weak response of the photomultiplier tube in the region in which these complexes are expected to emit, a low quantum yield for emission, or a quenching of the MLCT excited state by the expected intramolecular electron transfer to the rhodium metal center. The [{(bpy)2Ru(bpm)}2RhCl2]5+ system displays an emission at 800 nm, 34 supporting the role of intramolecular electrontransfer quenching of the MLCT excited state in the title trimetallics in quenching their MLCT emission.
This example demonstrates that the nature of the lowest lying transition is metal to ligand charge transfer in character. Additionally, this example demonstrates the Rh-based nature of the LUMO allowing this Rh metal to function as an electron acceptor within this structural motif. This established the metal to metal nature of the lowest lying excited state of these complexes.
- (1) Juris, A.; Balzani, V.; Barigelletti, F.; Campagna, S.; Belser, P.; von Zelewsky, A. Coord. Chem. ReV. 1988, 84, 85.
- (2) Kalyanasundaram, K. Coord. Chem. ReV. 1982, 46, 159.
- (3) (a) Strouse, G. F.; Schoonover, J. R.; Duesing, R.; Boyde, S.; Jones, W. E.; Meyer, T. J. Inorg. Chem. 1995, 34, 473.
- (b) Durham, B.; Caspar, J. V.; Nagle, J. K.; Meyer, T. J. J. Am. Chem. Soc. 1982, 104, 4803.
- (c) Anderson, P. A.; Strouse, G. F.; Treadway, J. A.; Keene, F. R.; Meyer, T. J. Inorg. Chem. 1996, 96, 759.
- (4) Balzani, V.; Moggi, L.; Scandola, F. In Supramolecular Photochemistry; Balzani, V., Ed.; NATO ASI Series 214; Reidel: Dordrecht, 1987;
p 1. - (5) Balzani, V.; Credi, A.; Raymo, F. M.; Stoddart, J. F. Angew. Chem., Int. Ed. 2000, 39, 3348.
- (6) Balzani, V.; Juris, A. Coord. Chem. ReV. 2001, 211, 97.
- (7) Balzani, V.; Ceroni, P.; Juris, A.; Venturi, M.; Campagna, S.; Puntoriero, F.; Serroni, S. Coord. Chem. Rev. 2001, 219-221, 545.
- (8) (a) Balzani, V.; Juris, A.; Venturi, M.; Campagna, S.; Serroni, S. Chem. ReV. 1996, 96, 759.
- (b) Balzani, V.; Campagna, S.; Dent, G.; Juris, A.; Seroni, S.; Venturi, M. Acc. Chem. Res. 1998, 31, 26.
- (9) Sauvage, J.-P.; Collin, J.-P.; Chambron, J.-C.; Guillerez, S.; Coudret, C.; Balzani, V.; Barigelletti, F.; De Cola, L.; Flamigni, L. Chem. ReV. 1994, 94, 993.
- (10) (a) Md. Meser, A.; MacDonnell, F. M. J. Am. Chem. Soc. 2000, 122, 11527.
- (b) Flamigni, L.; Encinas, S.; Barigelletti, F.; MacDonnell, F. M.; Kim, K.-J.; Puntoriero, F.; Campagna, S. Chem. Commun. 2000, 13, 1185.
- (c) Kim, M.-J., K.; MacDonnell, F. M.; Gimon-Kinsel, M. E.; DuBois, T.; Asgharian, N.; Griener, J. C. Angew. Chem., Int. Ed. 2000, 39, 615.
- (d) MacDonnell, F. M.; Kim, M.-J.; Bodige, S. Coord. Chem. ReV. 1999, 185, 535.
- (11) Petty, R. H.; Welch, B. R.; Wilson, L. J.; Bottomley, L. A.; Kadish, K. M. J. Am. Chem. Soc. 1980, 102, 611.
- (12) Fuchs, Y.; Lofters, S.; Dieter, T.; Shi, W.; Morgan, S.; Strekas, T. C.; Gafney, H. D.; Baker, A. D. J. Am. Chem. Soc. 1987, 109, 2691.
- (13) Hunziker, M.; Ludi, A. J. Am. Chem. Soc. 1977, 99, 7370.
- (14) Brewer, K. J.; Murphy, W. R.; Spurlin, S. R.; Petersen, J. D. Inorg. Chem. 1986, 25, 882.
- (15) Brauns, E.; Jones, S. W.; Clark, J. A.; Molnar, S. M.; Kawanishi, Y.; Brewer, K. J. Inorg. Chem. 1997, 36, 2861.
- (16) Rillema, D. P.; Allen, G.; Meyer, T. J.; Conrad, D. Inorg. Chem. 1983, 22, 1617.
- (17) Pavinato, R. A.; Walk, J. A.; McGuire, M. E. Inorg. Chem. 1993, 32, 1982.
- (18) Young, R. C.; Nagle, J. K.; Meyer, T. J.; Whitten, D. G. J. Am. Chem. Soc. 1978, 100, 4773.
- (19) Winkler, J. R.; Netzel, T. L.; Creutz, C.; Sutin, N. J. Am. Chem. Soc. 1987, 109, 2381.
- (20) Berger, R. M.; McMillin, D. R. Inorg. Chem. 1988, 27, 4245.
- (21) Arana, C. R.; Abruna, H. D. Inorg. Chem. 1993, 32, 194.
- (22) Vogler, L. M.; Brewer, K. J. Inorg. Chem. 1996, 35, 818.
- (23) Harriman, A.; Ziessel, R. Coord. Chem. Commun. 1998, 171, 331.
- (24) Constable, E. C.; Housecroft, C. E.; Schofield, E. R.; Encinas, S.; Armaroli, N.; Barigelletti, F.; Flamigni, L.; Figgemeier, E.; Vos, J. G. Chem. Commun. 1999, 869.
- (25) Indelli, M. T.; Bignozzi, C. A.; Scandola, F.; Collin, J. P. Inorg. Chem. 1998, 37, 6084.
- (26) Duati, M.; Fanni, S.; Vos, J. G. Inorg. Chem. Commun. 2000, 3, 68.
- (27) Hammarstrom, L.; Barigelletti, F.; Flamigni, L.; Indelli, M. T.; Armnaroli, N.; Calogero, G.; Guardigli, M.; Sour, A.; Collin, J. P.; Savauge, J. P. J. Phys. Chem. 1997, 101, 9061.
- (28) Maestri, M.; Armaroli, N.; Balzani, V.; Constable, E. C.; Thompson, A. M. Inorg. Chem. 1995, 34, 2759.
- (29) Jones, S. W.; Jordan, M. R.; Brewer, K. J. In Molecular and Supramolecular Photochemistry; Schanze, K. S., Ed.; Marcel Dekker: New York, 1999; Vol. 4, p 151.
- (30) Brewer, K. J. Comments Inorg. Chem. 1999, 21, 201.
- (31) (a) Molnar, S. M.; Nallas, G. N.; Bridgewater, J. S.; Brewer, K. J. J. Am. Chem. Soc. 1994, 116, 5206.
- (b) Bridgewater, J. S.; Vogler, L. M.; Molnar, S. M.; Brewer, K. J. Inorg. Chim. Acta 1993, 208, 179.
- (32) (a) Rasmussen, S. C.; Richter, M. M.; Yi, E.; Pace, H.; Brewer, K. J. Inorg. Chem. 1990, 29, 3926.
- (b) Molnar, S. M.; Jensen, G. E.; Vogler, L. M.; Jones, S. W.; Laverman, L.; Bridgewater, J. S.; Richter, M. M.; Brewer, K. J. J. Photochem. Photobiol., A: Chem. 1994, 80, 315.
- (33) Nallas, G. N. A.; Brewer, K. J. Inorg. Chim.
Acta 1996, 253, 7. - (34) Nallas, G. N.; Jones, S. W.; Brewer, K. J. Inorg. Chem. 1996, 35, 6974.
- (35) Kalyanasundaram, K.; Gratzel, M.; Nazeeruddin, Md. K. J Phys. Chem. 1992, 96, 5865.
- (36) (a) Indelli, M. T.; Scandola, F.; Collin, J.-P.; Sauvage, J.-P.; Sour, A. Inorg. Chem. 1996, 35, 303.
- (b) Indelli, M. T.; Scandola, F.; Flamingni, L.; Collin, J.-P. Sauvage, J.-P. Sour, A. Inorg. Chem. 1997, 36, 4247.
- (37) Scandola, F.; Argazzi, R.; Bignozzi, A.; Indelli, M. T. J. Photochem. Photobiol., A: Chem. 1994, 82, 191.
- (38) Nozaki, K.; Ohno, T.; Haga, M. J. Phys. Chem. 1992, 96, 10880.
- (39) Watzky, M. A.; Endicott, J. F.; Song, X.; Lei, Y.; Macatangay, A. Inorg. Chem. 1996, 35, 3463.
- (40) Lee, J. D.; Vrana, L. M.; Bullock, E. R.; Brewer, K. J. Inorg. Chem. 1998, 37, 3575.
- (41) (a) Lei, Y.; Buranda, T.; Endicott, J. F. J. Am. Chem. Soc. 1990, 112, 8820.
- (b) Macatangay, A. V.; Mazzetto, S. E.; Endicott, J. F. Inorg. Chem. 1999, 38, 5091.
- (42) Nawar, N. J. Organomet. Chem. 1999, 590, 217.
- (43) da Silva, A. C.; Piotrowski, H.; Mayer, P.; Polborn, K.; Severin, K. Eur. J. Inorg. Chem. 2001, 3, 685.
- (44) Ranco, S. E.; Thompson, D. W.; Gahan, S. L.; Petersen, J. D. Inorg. Chem. 1998, 27, 2020.
- (45) Sullivan, B. P.; Calvert, J. M.; Meyer, T. J. Inorg. Chem. 1980, 19, 1404.
- (46) Vogler, L. M.; Franco, C.; Jones, S. W.; Brewer, K. J. Inorg. Chim. Acta 1994, 221, 55.
- (47) Swavey, S.; Fang, Z.; Brewer, K. J. Inorg. Chem., in press.
- (48) Gennett, T.; Milner, D. F.; Weaver, M. J. J. Phys. Chem. 1985, 89, 2787.
- (49) Brewer, K. J.; Calvin, M.; Lumpkin, R. S.; Otvos, J. W.; Spreer, L. O. Inorg. Chem. 1989, 28, 4446.
- (50) (a) Kew, G.; DeArmond, K.; Hanck, K. J. Phys. Chem. 1974, 78, 727. (b) Kew, G.; Hanck, K.; DeArmond, K. J. Phys. Chem. 1975, 79, 1828.
- (51) Krause, E.; Ferguson, J. Prog. Inorg. Chem. 1989, 37, 293.
- (52) Vrana, L. M.; Brewer, K. J. J. Photochem. Photobiol., A 1997, 109, 2013.
- (53) J. Organomet. Chem. 1998, 554, 29.
Recent emphasis has been placed on developing reagents capable of cleaving DNA, applicable as structural probes and therapeutic agents, with many transition metal complexes being reported.1-18 Photochemical approaches are of particular interest as they offer reaction control and can be highly targeted.10-15,19 One popular approach involves the sensitization of molecular oxygen.5,7,8,20
The development of photosensitizers that absorb low energy light, are tunable, and function in the absence of molecular oxygen is of interest. Oxygen independent systems function under conditions of low oxygen content and often have a different mechanism of photocleavage.16 A photosensitizer which can be excited with low energy light can avoid the base damage induced by UV light.21,22
Rhodium and ruthenium complexes photocleave DNA. Photolysis at 310 nm of rhodium(III) complexes of phi (9,10-phenanthrenequinone diimine) leads to hydrogen abstraction from the 3′-carbon of deoxyribose, leading to DNA cleavage.23 Cleavage selectivity can be modulated by ancillary24 and active25 ligand variation or by tethering to DNA.26-29 [Rh(phi)2(phen)]3+ has recently been shown to stabilize duplex DNA inhibiting transcription.30 Rh2(O2CCH3)4L2 (L=H2O14 or PPh3 31) has exhibited the ability to photocleave DNA when irradiated in the presence of electron acceptors. Studies have shown site specific oxidative cleavage of DNA using [RuIV(tpy)(bpy)O]2+ and [RuIII(tpy)(bpy)OH]2+ (tpy=2,2′:6′,2″-terpyridine.32,33 Photoexcitation of ruthenium(II) (polypyridyl systems has resulted in oxidative damage to DNA in the presence of an electron acceptor34-36 and cleavage by oxygen sensitization.5,7,8 Rh(III) complexes intercalated into DNA serve as electron acceptors for excited Ru chromophores via long-range electron transfer.37,38
Trimetallic complexes coupling light absorbing ruthenium centers to reactive metal centers have been of interest. [{(bpy)2Ru(BL)}2MCl2]5+ (M=Rh or Ir and BL=2,3-bis(2-pyridyl)pyrazine (dpp)39 or 2,2′-bipyrimidine (bpm)40) complexes, shown in FIG. 7 display quite varied electrochemical properties and differing lowest lying excited states. They are good chromophores with the high energy region of the electronic absorption spectra dominated by ligand based (π to π*) transitions. The visible region contains metal to ligand charge transfer (MLCT) transitions to both acceptor ligands with the BL transition being the lowest energy.
The electronic absorption spectra of these supramolecular complexes are shown in FIG. 8 . All three complexes possess lowest lying Ru(d π) to BL CT bands that occur in the low energy visible region. For [{(bpy)2Ru(dpp)}2RhCl2]5+ and [{(bpy)2Ru(dpp)}2IrCl2]5+, the Ru(dπ) to dpp(π*) CT transition occurs at 525 nm. The Ru(dπ) to bpm(π to π*) CT transition for [{(bpy)2Ru(bpm)}2RhCl2]5+ occurs at 594 nm. The Ir and Rh analogues, [({(bpy)2Ru(dpp)}2MCl2]5+, have spectroscopy that is virtually identical owing to their similar supramolecular structure and the dominance of the Ru light absorbers on the spectroscopic properties of these systems. The electrochemical properties vary with BL and M for [{(bpy)2Ru(BL)}2MCl2]5+, summarized in Table 3. The complexes exhibit a single reversible oxidation wave in the anodic region (1.56 and 1.70 V vs Ag/AgCl) attributed to the overlapping RuIII/II redox couple for the two equivalent Ru centers. [{(bpy)2Ru(bpm)}2RhCl2]5+ exhibits reversible bridging ligand reductions prior to reduction of the central Rh metal.40 [{(bpy)2Ru(dpp)}2RhCl2]5+ undergoes an irreversible two electron reduction of the Rh(III) metal center prior to reduction of the dpp BL. This orbital inversion, FIG. 9 , of the dpp(π*) and Rh(dσ*) orbitals, allows the Rh to function as an electron acceptor giving a lowest lying, Ru to Rh metal to metal charge transfer (MMCT) excited state in this complex. It is this state we exploit for DNA photocleavage.
| TABLE 3 |
| Electrochemical Properties for a Series of Ru(II) and Ru(II)/Rh(III)/ |
| Ru(II) Trimetallic Complexes where bpy = 2,2′-Bipyridine, |
| dpp = 2,3-Bis(2-pyridyl)pyrazine, and |
| bpm = 2,2′-Bipyrimidine complex |
| Complex | E1/2, Va | assignment |
| [{(bpy)2Ru(dpp)}2RhCl2](PF6)5 | 1.6 | 2RuIII/II |
| −0.39b | RhIII/I | |
| −0.79 | dpp, dpp/dpp, dpp− | |
| −1.02 | dpp, dpp−/dpp−dpp− | |
| [{(bpy)2Ru(bpm)}2RhCl2](PF6)5 | 1.7 | 2RuIII/II |
| −0.13 | bpm, bpm/bpm, bpm | |
| −0.26 | bpm, bpm−/bpm−, bpm− | |
| −0.78 | RhIII/I | |
| [{(bpy)2Ru(dpp)}2IrCl2](PF6)5 | 1.56 | 2RuIII/II |
| −0.39 | dpp, dpp/dpp, dpp− | |
| −0.54 | dpp, dpp−/dpp dpp | |
| aPotentials reported versus the Ag/AgCl (0.29 V vs NHE) reference electrode in 0.1 M Bu4NPF6,CH3CN. | ||
| bEp c value. | ||
The lack of a Rh(dσ*) LUMO in the [{(bpy)2Ru(bpm)}2RhCl2]5+ system allowed us to use this as a very similar supramolecular architecture control system with a lowest lying MLCT state. The Ir analogue, [{(bpy)2Ru(dpp)}2IrCl2]5+, served as a spectroscopically matched system with a lowest lying MLCT state.
pUC18 and pBluescript were used to probe pbotocleavage of DNA by gel electrophoresis.14,26,41,42 pUC18 plasmid is 2686 bp (Bayou Biolabs). Irradiation used a 1000 W xenon arc lamp, a water IR filter, and a 475 nm cut off filter. Solutions were 3.5 μM in metal complex and 6.9 mM in phosphate buffer (pH=7) and allowed for ionic association of the cationic metal complexes with DNA. Dexoygenation was accomplished by bubbling with Ar for 30 min prior to the photolysis of the samples in an airtight cell blanketed with Ar.
To explore the role of the Rh LUMO, resulting in an MMCT excited state, on the DNA photocleavage, the bpm analogue [{(bpy)2Ru(bpm)}2RhCl2]5+ and the Ir analogue [{(bpy)2Ru(dpp)}2IrCl2]5+, which contain inaccessible Rh(dσ*) and Ir(dσ*) orbitals,39,40 were studied for their ability to photocleave DNA. The Ir analogue has nearly identical electronic absorption spectroscopy to that of the Rh complex. This allows it to function well as a control system possessing a lowest lying MLCT state. The results of this study are shown in FIG. 10 b. Lanes 1 and 2 (FIG. 10 b) are the plasmid controls. Lanes 3 and 5 reveal that when the plasmid is incubated at 37° C. in the presence of [{(bpy)2Ru(bpm)}2RhCl2]5+ or [{(bpy)2Ru(dpp)}2IrCl2]5+, respectively, at a 1:5 metal complex to base pair ratio, no DNA cleavage occurs. Similar solutions irradiated (λirr≧475 nm) for 10 min (lanes 4 and 6), in the absence of molecular oxygen, also do not result in DNA cleavage. Similar studies in the presence of oxygen also do not result in DNA cleavage.
These results indicate that our mixed-metal supramolecular complex, [{(bpy)2Ru(dpp)}2RhCl2]5+, is capable of DNA photocleavage and similar systems without a Rh(dσ*) based LUMO do not display this behavior. This illustrates that our modifications of the coordination environment, yielding the desired orbital ordering, [{(bpy)2Ru(dpp)}2RhCl2]5+, creates a system that photocleaves DNA via an MMCT excited state. Additionally, photocleavage can occur in the absence of molecular oxygen.
This study presents a new structural motif for DNA photocleavage agents, functioning from a previously unstudied excited state for this application. A frank cleavage is observed consistent with reactivity arising from the photogenerated Rh(II) site. This supramolecular architecture allows for substitution of components to tune properties of these systems, allowing for the development of many new complexes that should display similar reactivity.
- (1) Absalon, M. J.; Wu, w.; Stubbe, J. Biochemistry 1995, 34, 2076.
- (2) Tullius, T. D. Nature 1988, 332, 663.
- (3) Sardesai, N. Y.; Zimmermann, K.; Barton, J. K. J. Am. Chem. Soc. 1994, 116, 7502.
- (4) Mrksich, M.; Dervan, P. B. J. Am. Chem. Soc. 1995, 117, 3325.
- (5) Hergueta-Bravo, A.; Jimenez-Hernandez, M. E.; Montero, F.; Oliveros, E.; Orellana, G. J. Phys. Chem. B. 2002, 106, 4010.
- (6) Juskowiak, B.; Dominiak, A.; Takenaka, S.; Takagi, M. Photochem. Photobiol. 2001, 74, 391.
- (7) Moucheron, C.; Kirsch-DeMesmaeker, A.; Kelly, J. M. J. Photochem. Photobiol.,
B 1997, 40, 91. - (8) Tossi, A. B.; Kelly, J. M. Photochem. Photobiol. 1989, 49, 545.
- (9) Barton, J. K.; Raphael, A. L. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 6460.
- (10) Barton, J. K.; Holmlin, R. E. Inorg. Chem. 1995, 34, 7.
- (11) Fleisher, M. B.; Waterman, K. C.; Turro, N. J.; Barton, J. K. Inorg. Chem. 1986, 25, 3549.
- (12) Bhattacharya, S.; Mandal, S. S. Chem. Commun. 1996, 1515.
- (13) Farinas, E.; Tan, J. D.; Baidya, N.; Mascharak, P. K. J. Am. Chem. Soc. 1993, 115, 2996.
- (14) Fu, P. K.-L.; Bradley, P. M.; Turro, C. Inorg. Chem. 2001, 40, 2476.
- (15) Nunez, M. E.; Rajski, S. R.; Barton, J. K. Methods Enzymol. 2000, 319, 165.
- (16) Armnitage, B. Chem. ReV. 1998, 98, 1171.
- (17) Dunn, D. A.; Lin, V. H.; Kochevar, I. E. Biochemistry 1992, 31, 11620.
- (18) Paillous, N.; Vincendo, P. J. Photochem. Photobiol.,
B 1993, 20, 203. - (19) Kim, J.; Sistarc, M. F.; Carter, P. J.; Thorp, H. H. Coord. Chem. ReV. 1998, 171, 341.
- (20) Bonnett, R. Chemical Aspects of Photodynamic Therapy; Taylor and Francis, Inc.: Philadelphia, 2000; Vol. 1,
Chapter 4, pp 57-70. - (21) Boutorine, A. S.; Brault, D.; Takasugi, M.; Delgado, O.; Helene, C. J. Am. Chem. Soc. 1996; 118, 9469.
- (22) Murray, V.; Martin, R. Nucleic Acids Res. 1994, 22, 506.
- (23) Sitlani, A.; Long, E. C.; Pyle, A. M.; Barton, J. K. J. Am. Chem. Soc. 1992, 114, 2303.
- (24) Turro, C.; Hall, D. B.; Chen, W.; Zuilhof, H.; Barton, J. K.; Turro, N. J. J. Phys. Chem. A 1998, 102, 5708.
- (25) (a) Jackson, B. A.; Henling, L. M.; Barton, J. K. Inorg. Chem. 1999, 38, 6218. (b) Jackson, B. A.; Barton, J. K.
Biochemistry 2000, 39, 6176. - (26) Copeland, K. D.; Fitzsimons, M. P.; Houser, R. P.; Barton, J. K. Biochemistry 2002, 41, 343.
- (27) Williams, T. T.; Barton, J. K. J. Am. Chem. Soc. 2002, 124, 1840.
- (28) Hall, D. B.; Holmlin, R. E.; Barton, J. K. Nature 1996, 382, 731.
- (29) Nunez, M. E.; Barton, J. K. Curr. Opin. Chem. Biol. 2000, 4, 199.
- (30) Fu, P. K.-L.; Turro, C. Chem. Commun. 2001, 279.
- (31) Bradley, P. M.; Fu, P. K.-.L.; Turro, C. Comments Inorg. Chem. 2001, 22, 393.
- (32) Cheng, C. C.; Goll, J. G.; Neyhart, G. A.; Walch, T. W.; Singh, P.; Thorp, H. H. J. Am. Chem. Soc. 1995, 117, 2970.
- (33) Farrer, B. T.; Thorp, H. H. Inorg. Chem. 2000, 39, 44.
- (34) Stemp, E. D. A.; Arkin, M. R.; Barton, J. K. J. Am. Chem. Soc. 1997, 119, 2921.
- (35) Delaney, S.; Pascaly, M.; Bhattacharya, P. K.; Han, K.; Barton, J. K. Inorg. Chem. 2002.
- (36) Ambroise, A.; Maiya, B. G. Inorg. Chem. 2000, 39, 4264.
- (37) Purugganan, M. D.; Kumar, C. V.; Turro, N. J. Science 1988, 241, 1645.
- (38) Arkin, M. R.; Stemp, E. D. A.; Holmlin, R. E.; Barton, J. K.; Hormann, A.; Olsen, E. J. C.; Barbara, P. F. Science 1996, 273, 475.
- (39) Molnar, S. M.; Jensen, G. E.; Vogler, L. M.; Jones, S. W.; Layerman, L.; Bridgewater, J. S.; Richter, M. M.; Brewer, K. J. J. Photochem. Photobiol., A 1994, 80, 315.
- (40) Nallas, G. N.; Jones, S. W.; Brewer, K. J. Inorg. Chem. 1996, 35, 6974.
- (41) Kumar, C. V.; Tan, W. B.; Betts, P. W. J. Inorg. Biochem. 1997, 68, 177.
Photoinduced inhibition of Vero cell replication by the supramolecular complex [{(bpy)2Ru(dpp)}2RhCl2](PF6)5 was investigated. All experiments were carried out with 0.5 mg/mL of [{(bpy)2Ru(dpp)}2RhCl2](PF6)5 in MEM media, and the results are shown in FIG. 11A . This cell line normally replicates once each 24 hours. The line with diamond symbols (⋄) shows the growth of the Vero cells after irradiation for 10 minutes at λ>475 nm. As can be seen, exposure to light alone did not impact this replication. The line with square symbols (□) shows the results obtained when Vero cells are incubated in the dark with various concentrations of [{(bpy)2Ru(dpp)}2RhCl2](PF6)5. As can be seen, exposure to [{(bpy)2Ru(dpp)}2RhCl2](PF6)5 alone (i.e. without illumination) did not impact replication.
In marked contrast, photolysis at λ>475 nm after incubation with [{(bpy)2Ru(dpp)}2RhCl2](PF6)5 greatly inhibits cell replication, as evidenced by the line with circle symbols (∘).
This example demonstrates that the complex [{(bpy)2Ru(dpp)}2RhCl2](PF6)5 is not toxic to cells in the dark. It further demonstrates that the complex [{(bpy)2Ru(dpp)}2RhCl2](PF6)5 is able to greatly inhibit the replication of cells after exposure of cells with this complex to low energy visible light. Thus, the complexes of the present invention display photodynamic action leading to inhibition of cell replication.
The concentration dependence of photoinduced inhibition of cell replication by the supramolecular complex [{(bpy)2Ru(dpp)}2RhCl2]Cl5 is shown in FIG. 11B . The line with circular symbols shows the impact on Vero cell growth of the incubation of the cells in the dark with the indicated concentrations of [{(bpy)2Ru(dpp)}2RhCl2]Cl5. The line with square symbols shows the growth of Vero cells incubated with the same concentrations of [{(bpy)2Ru(dpp)}2RhCl2]Cl5, and subsequent irradiation for 10 minutes at λ>475 nm. As can be seen, irradiation at λ>475 nm greatly inhibits the ability of Vero cells to replicate. This is likely due to photoinduced death of the irradiated cells.
This example demonstrates that the complex [{(bpy)2Ru(dpp)}2RhCl2]Cl5 is not toxic to cells in the dark at a wide range of concentrations. It further demonstrates that the complex [{(bpy)2Ru(dpp)}2RhCl2]Cl5 is able to greatly inhibit the replication of cells after exposure of cells with this complex to low energy visible light and demonstrates the concentration needed for such action. Thus, the complexes of the present invention display photodynamic action leading to inhibition of cell replication.
The ability of several supramolecular complexes to photocleave DNA was assayed and the results are shown in FIG. 12A-C . Details of the experiments are given in the figure legends. The complexes utilized were A, [{(bpy)2Os(dpp)}2RhCl2](PF6)5; B, [{(tpy)RuCl(dpp)}2RhCl2](PF6)3; and C, [{(tpy)RuCl(bpm)}2RhCl2](PF6)3. As can be seen, each complex displayed the ability to efficiently cleave DNA upon activation by low energy, visible light.
This example demonstrates that many components as described herein can be successfully incorporated into the generic supramolecular metallic complex of the present invention and result in the production of a complex that successfully cleaves DNA.
While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims. Accordingly, the present invention should not be limited to the embodiments as described above, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein.
Claims (9)
1. A method for cleaving DNA comprising the steps of:
combining said DNA with a supramolecular complex to form a mixture, said supramolecular complex comprising:
at least one metal to ligand charge transfer (MLCT) light absorbing metal,
at least one bridging π-acceptor ligand, and
an electron acceptor metal selected from the group consisting of rhodium(III), platinum(IV), cobalt(III), and iridium(III),
wherein said supramolecular complex is present in sufficient quantity to bind to and cleave said DNA, and
exposing said mixture to light or radiant energy sufficient to activate said supramolecular complex to cleave said DNA,
wherein said step of exposing said mixture to light or radiant energy induces the production of a metal-to-metal charge transfer state within said supramolecular complex, and wherein said metal-to-metal charge transfer state mediates the cleavage of said DNA.
2. The method of claim 1 wherein said at least one metal to ligand charge transfer (MLCT) light absorbing metal is selected from the group consisting of ruthenium(II), osmium(III), rhenium(I), iron(II) and platinum(II).
3. The method of claim 1 , wherein said at least one bridging π-acceptor ligand is selected from the group consisting of 2,3-bis(2-pyridyl)pyrazine; 2,2′-bipyridimidine; 2,3-bis(2-pyridyl)quinoxaline; and 2,3,5,6,-tetrakis(2-pyridyl)pyrazine.
4. The method of claim 1 , wherein said supramolecular complex further comprises at least one terminal π-acceptor ligand.
5. The method of claim 4 , wherein said at least one terminal π-acceptor ligand is selected from the group consisting of 2,2′-bipyridine; 2,2′:6′,2″-terpyridine; triphenylphosphine; and 2,2′-phenylpyridine and diethylphenylphosphine.
6. The method of claim 1 , wherein said DNA is in a hyperproliferating cell.
7. The method of claim 6 , wherein said hyperproliferating cell is selected from the group consisting of leukemia cells, ovarian cancer cells, Burkitt's lymphoma cancer cells, breast cancer cells, gastric cancer cells, and testicular cancer cells.
8. The method of claim 1 , wherein said DNA is in a non-malignant hyperproliferating cell.
9. The method of claim 8 , wherein said non-malignant hyperproliferating cell is associated with psoriasis, warts or macular degeneration in an organism.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/610,729 US8445475B2 (en) | 2002-02-01 | 2009-11-02 | Supramolecular complexes as photoactivated DNA cleavage agents |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35286502P | 2002-02-01 | 2002-02-01 | |
| US10/355,258 US6962910B2 (en) | 2002-02-01 | 2003-01-31 | Supramolecular complexes as photoactivated DNA cleavage agents |
| US11/184,840 US7612057B2 (en) | 2002-02-01 | 2005-07-20 | Supramolecular complexes as photoactivated DNA cleavage agents |
| US12/610,729 US8445475B2 (en) | 2002-02-01 | 2009-11-02 | Supramolecular complexes as photoactivated DNA cleavage agents |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/184,840 Continuation US7612057B2 (en) | 2002-02-01 | 2005-07-20 | Supramolecular complexes as photoactivated DNA cleavage agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20100047910A1 US20100047910A1 (en) | 2010-02-25 |
| US8445475B2 true US8445475B2 (en) | 2013-05-21 |
Family
ID=28045032
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/355,258 Expired - Lifetime US6962910B2 (en) | 2002-02-01 | 2003-01-31 | Supramolecular complexes as photoactivated DNA cleavage agents |
| US11/184,840 Expired - Lifetime US7612057B2 (en) | 2002-02-01 | 2005-07-20 | Supramolecular complexes as photoactivated DNA cleavage agents |
| US12/610,729 Expired - Lifetime US8445475B2 (en) | 2002-02-01 | 2009-11-02 | Supramolecular complexes as photoactivated DNA cleavage agents |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/355,258 Expired - Lifetime US6962910B2 (en) | 2002-02-01 | 2003-01-31 | Supramolecular complexes as photoactivated DNA cleavage agents |
| US11/184,840 Expired - Lifetime US7612057B2 (en) | 2002-02-01 | 2005-07-20 | Supramolecular complexes as photoactivated DNA cleavage agents |
Country Status (1)
| Country | Link |
|---|---|
| US (3) | US6962910B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016116859A1 (en) | 2015-01-19 | 2016-07-28 | Theralase Technologies, Inc. | Metal-glycoprotein complexes and their use as chemotherapeutic compounds |
| US10111936B2 (en) | 2015-01-19 | 2018-10-30 | Theralase Technologies, Inc. | Metal-glycoprotein complexes and photodynamic therapy of immune privileged sites with same |
| US10335608B2 (en) | 2016-04-20 | 2019-07-02 | Theralase Technologies, Inc. | Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics |
| US11464798B2 (en) | 2017-05-11 | 2022-10-11 | Theralase Technologies Inc. | Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same |
| US11793818B2 (en) | 2018-03-26 | 2023-10-24 | Theralase Technologies, Inc. | Method for treating conditions associated with hyperproliferating cells comprising combined administration of a cannabinoid receptor agonist and radiation therapy |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6962910B2 (en) * | 2002-02-01 | 2005-11-08 | Virginia Tech Intellectual Properties, Inc. | Supramolecular complexes as photoactivated DNA cleavage agents |
| US7811675B2 (en) * | 2002-11-06 | 2010-10-12 | The University Of Hong Kong | Electroluminescent metallo-supramolecules with terpyridine-based groups |
| US7122171B2 (en) * | 2004-12-02 | 2006-10-17 | Virginia Tech Intellectual Properties, Inc. | Supramolecular complexes as photocatylysts for the production of hydrogen from water |
| US20060256133A1 (en) * | 2005-11-05 | 2006-11-16 | Outland Research | Gaze-responsive video advertisment display |
| WO2007072018A2 (en) * | 2005-12-21 | 2007-06-28 | Oxford Biosensors Ltd | Redox mediators |
| DK2032701T3 (en) * | 2006-06-23 | 2014-02-10 | Alethia Biotherapeutics Inc | Polynucleotides and polypeptides involved in cancer |
| WO2008031017A2 (en) * | 2006-09-07 | 2008-03-13 | Virginia Tech Intellectual Properties, Inc. | Supramolecular metallic complexes exhibiting both dna binding and photocleavage |
| CA2681521A1 (en) * | 2007-03-21 | 2008-09-25 | Virginia Tech Intellectual Properties, Inc. | Supramolecular complexes as photocatalysts for reduction of substrates |
| CN102015743A (en) * | 2008-02-08 | 2011-04-13 | 本尤明·A·科恩 | Ruthenium compounds and compositions |
| KR20110084280A (en) | 2008-11-03 | 2011-07-21 | 알레시아 바이오쎄라퓨틱스 인코포레이티드 | Antibodies that specifically block the biological activity of a tumor antigen |
| KR101993259B1 (en) | 2011-03-31 | 2019-06-27 | 에이디씨 테라퓨틱스 에스에이 | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
| EA201992513A1 (en) | 2012-01-09 | 2020-05-31 | Адс Терапьютикс Са | BREAST CANCER TREATMENT METHOD |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457195A (en) | 1989-12-21 | 1995-10-10 | Board Of Regents, The University Of Texas System | Sapphyrin derivatives and conjugates |
| US6537973B1 (en) * | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
| US6630128B1 (en) | 1998-08-28 | 2003-10-07 | Destiny Pharma Limited | Porphyrin derivatives their use in photodynamic therapy and medical devices containing them |
| US7612057B2 (en) * | 2002-02-01 | 2009-11-03 | Virginia Tech Intellectual Properties, Inc. | Supramolecular complexes as photoactivated DNA cleavage agents |
-
2003
- 2003-01-31 US US10/355,258 patent/US6962910B2/en not_active Expired - Lifetime
-
2005
- 2005-07-20 US US11/184,840 patent/US7612057B2/en not_active Expired - Lifetime
-
2009
- 2009-11-02 US US12/610,729 patent/US8445475B2/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457195A (en) | 1989-12-21 | 1995-10-10 | Board Of Regents, The University Of Texas System | Sapphyrin derivatives and conjugates |
| US6537973B1 (en) * | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
| US6630128B1 (en) | 1998-08-28 | 2003-10-07 | Destiny Pharma Limited | Porphyrin derivatives their use in photodynamic therapy and medical devices containing them |
| US7612057B2 (en) * | 2002-02-01 | 2009-11-03 | Virginia Tech Intellectual Properties, Inc. | Supramolecular complexes as photoactivated DNA cleavage agents |
Non-Patent Citations (3)
| Title |
|---|
| Fang et al. "DNA Binding of Mixed-Metal Supramolecular Ru, Pt Complexes". Inorganic Chemistry Communications. 2002; 5:1078-1081. * |
| Lee Goldman et al., (Editors): Cecil Textbook of Medicine; 21st Edition. W.B. Saunders Company, pp. 1060-1074 (2000). |
| Milkevitch et al. "Mixed-Metal Polymetallic Platinum Compelxes Designed to Interact with DNA". Inorganica Chimica Acta. 1997; 264:249-256. * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016116859A1 (en) | 2015-01-19 | 2016-07-28 | Theralase Technologies, Inc. | Metal-glycoprotein complexes and their use as chemotherapeutic compounds |
| US9737565B2 (en) | 2015-01-19 | 2017-08-22 | Theralase Technologies, Inc. | Metal-glycoprotein complexes and their use as chemotherapeutic compounds |
| US10111936B2 (en) | 2015-01-19 | 2018-10-30 | Theralase Technologies, Inc. | Metal-glycoprotein complexes and photodynamic therapy of immune privileged sites with same |
| US10335608B2 (en) | 2016-04-20 | 2019-07-02 | Theralase Technologies, Inc. | Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics |
| US11464798B2 (en) | 2017-05-11 | 2022-10-11 | Theralase Technologies Inc. | Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same |
| US11793818B2 (en) | 2018-03-26 | 2023-10-24 | Theralase Technologies, Inc. | Method for treating conditions associated with hyperproliferating cells comprising combined administration of a cannabinoid receptor agonist and radiation therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100047910A1 (en) | 2010-02-25 |
| US6962910B2 (en) | 2005-11-08 |
| US20050272713A1 (en) | 2005-12-08 |
| US7612057B2 (en) | 2009-11-03 |
| US20030180767A1 (en) | 2003-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8445475B2 (en) | Supramolecular complexes as photoactivated DNA cleavage agents | |
| Schmitt et al. | Ruthenium porphyrin compounds for photodynamic therapy of cancer | |
| Li et al. | Ru (II) polypyridyl complexes derived from tetradentate ancillary ligands for effective photocaging | |
| Bonnet et al. | Ruthenium-decorated lipid vesicles: light-induced release of [Ru (terpy)(bpy)(OH2)] 2+ and thermal back coordination | |
| Biancalana et al. | α-Diimines as versatile, derivatizable ligands in ruthenium (II) p-cymene anticancer complexes | |
| Higgins et al. | Redox, spectroscopic, and photophysical properties of Ru− Pt mixed-metal complexes incorporating 4, 7-diphenyl-1, 10-phenanthroline as efficient DNA binding and photocleaving agents | |
| Yin et al. | In vitro multiwavelength PDT with 3IL states: Teaching old molecules new tricks | |
| Luengo et al. | Trackable metallodrugs combining luminescent Re (I) and bioactive Au (I) fragments | |
| Bischof et al. | Synthesis, spectroscopic properties, and photoinduced CO-release studies of functionalized ruthenium (II) polypyridyl complexes: Versatile building blocks for development of CORM–peptide nucleic acid bioconjugates | |
| Schatzschneider | Photoactivated biological activity of transition‐metal complexes | |
| Williams et al. | Synthesis, characterization, and DNA binding properties of a series of Ru, Pt mixed-metal complexes | |
| Ma et al. | Platinum-containing heterometallic complexes in cancer therapy: advances and perspectives | |
| US8148360B2 (en) | Supramolecular metallic complexes exhibiting both DNA binding and photocleavage | |
| Lam et al. | Luminescent ruffled iridium (iii) porphyrin complexes containing N-heterocyclic carbene ligands: structures, spectroscopies and potent antitumor activities under dark and light irradiation conditions | |
| Bradley et al. | Direct DNA photocleavage by a new intercalating dirhodium (II/II) complex: comparison to Rh2 (μ-O2CCH3) 4 | |
| Rani-Beeram et al. | A fluorinated ruthenium porphyrin as a potential photodynamic therapy agent: synthesis, characterization, DNA binding, and melanoma cell studies | |
| Rose et al. | Ruthenium nitrosyls derived from polypyridine ligands with carboxamide or imine nitrogen donor (s): Isoelectronic complexes with different NO photolability | |
| Toubia et al. | Synthesis and anticancer activity of gold porphyrin linked to malonate diamine platinum complexes | |
| Burya et al. | Photoinduced ligand exchange and covalent DNA binding by two new dirhodium bis-amidato complexes | |
| Pickens et al. | Visible light-activated CO release and 1O2 photosensitizer formation with Ru (II), Mn (I) complexes | |
| Divya et al. | Single-pot self-assembly of heteroleptic Mn (I)-based aminoquinonato-bridged ester/amide-functionalized dinuclear metallastirrups: potential anticancer and visible-light-triggered CORMs | |
| Pordel et al. | Release of CO and production of 1O2 from a Mn-BODIPY Photoactivated CO releasing molecule with visible light | |
| Yano et al. | Anticancer activity of heterodinuclear ruthenium (II)–platinum (II) complexes as photochemotherapeutic agents | |
| Nakae et al. | CO release from N, C, S-pincer iron (III) carbonyl complexes induced by visible-to-NIR light irradiation: mechanistic insight into effects of axial phosphorus ligands | |
| Bjelosevic et al. | Exposing “Bright” metals: promising advances in photoactivated anticancer transition metal complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: VIRGINIA POLYTECHNIC INSTITUTE & STATE UNIVERSITY, Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BREWER, KAREN J.;SWAVEY, SHAWN;SIGNING DATES FROM 20050527 TO 20050531;REEL/FRAME:023460/0532 Owner name: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.,VIRGIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY;REEL/FRAME:023460/0541 Effective date: 20050607 Owner name: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC., VIRGI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY;REEL/FRAME:023460/0541 Effective date: 20050607 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |